


Labelled Ligands and Cloned Receptors


2006/2007



BIOTREND offers more than 5000 antibodies, over 1200 **Neurochemicals** and pharmacological standards as well as 1600 **Radiochemicals** and ligands.

This special brochure covers the pharmacological action of our ligands and receptors in alphabetical order.

If you do not find a product, we will be glad to offer custom iodination or tritiation. See page 36 / 37.



Gunther Jaeger
Managing Director
BIOTREND

BIO  [®]
TREND

4	<i>Adenosines • Purinergics</i>
5	<i>Adrenergics</i>
6	<i>Adrenomedullin • Angiotensins • Apelins</i>
7	<i>Benzodiazepins • GABA-ergics</i>
8	<i>Bombesins • Bradykinins • Cannabinoids</i>
9	<i>CGRP's • Chemokines</i>
11	<i>Cholecystokinin and Gastrin • Cholinergics</i>
12	<i>Corticotropin Releasing Factors (CRF)</i>
13	<i>Dopaminergics</i>
14	<i>Endothelins</i>
15	<i>Enzyme Inhibitors • GABA • Glycine Receptor</i>
16	<i>Galanins • Ghrelins • Glutamate Receptor Compounds, Iontropic / Excitatory Amino Acids</i>
17	<i>Glutamate Receptor Compounds, Metabotropic / Excitatory Amino Acids</i>
18	<i>Growth Factors • Histaminergics</i>
19	<i>Imidazolines • Ion Channel Modulators • Leukotrienes</i>
20	<i>MCH, Melanin Concentrating Hormone • Melanocortin Receptors • Melatonins</i>
21	<i>Miscellaneous</i>
22	<i>Neuropeptides</i>
23	<i>Natriuretic Peptides</i>
24	<i>Opioids and Sigma Ligands</i>
25	<i>Orexins</i>
26	<i>Peptides/Miscellaneous</i>
27	<i>Prostanoids</i>
28	<i>Retinoids • Serotonergics</i>
29	<i>Signal Transduction Agents</i>
31	<i>Somatostatins / SRIF • Steroids</i>
33	<i>Tachikinins • Vasopressins</i>
36	<i>Custom Synthesis and Labelling Request Form</i>
37	<i>Technical Service and Custom Labelling</i>
38	<i>Enquiry</i>

Adenosines / Purinergics							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
EBT-ES-010-M	Adenosine A ₁ Receptor, Human	lyophilized membrane total protein	1.5 and 3.1 pmol/mg	receptor	A ₁	200 U / vial	557,75
BT-ES-010-CF	Adenosine cells , A ₁ , Human	frozen cells	functional GPCR testing	cAMP	A ₁	100 units	517,50
BC101520	Adenosine A _{1b} Receptor, Human	lyophilized membrane	1.0 pmol/mg total protein	receptor	A _{1b}	200 U / 4 vials	655,50
BT-ES-011-M	Adenosine A _{2a} Receptor, Human	lyophilized membrane	4.9 and 7.4 pmol/mg total protein	receptor	A _{2a}	200 U / vial	557,75
BT-ES-013-M	Adenosine A _{2b} Receptor, Human	lyophilized membrane	6.1 and 9.1 pmol/mg total protein	receptor	A _{2b}	200 U / vial	557,75
BC101820	Adenosine A _{2c} Receptor, Rat	lyophilized membrane	0.3 pmol/mg total protein	receptor	A _{2c}	200 U / 4 vials	655,50
BT-ES-012-M	Adenosine A ₃ Receptor, Human	lyophilized membrane	4.6 and 7 pmol/mg total protein	receptor	A ₃	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0287	Adenosine, [2,8-³H] M.W. 267.2	Sterile water 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	endogenous		1 mCi / 37 MBq	264,50
ART-0338	Adenosine 5'-monophosphate, [8-³H], ammonium salt M.W. 381.3	Ethanol:water (1:1) 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol	endogenous	P ₂	250 µCi / 9.25 MBq	287,50
ART-0164	Adenosine 5'-triphosphate, [2,8-³H], tetrasodium salt M.W. 597.3	Ethanol:water (1:1) 1 mCi/ml	15-30 Ci/mmo 0.55-1.11 TBq/mmol	endogenous		250 µCi / 9.25 MBq	218,50
A3-AI-162	APNEA, [¹²⁵I] , N6-[2-(4-Aminophenyl)ethyl]adenine	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	A ₃	50 µCi / 1.85 MBq	1.753,75
ART-1505	Cyclopentyladenosine, [2-³H] M.W. 335.36	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol"	agonist	A ₁	50 µCi / 1.85 MBq	Enquire
ART-1456	HEMADO, [³H] 2-(1-Hexynyl)-N-methyladenosine M.W. 361.40	Ethanol:water (1:1) 1 mCi/ml	20-50 Ci/mmol 0.74-1.85 TBq/mmol	agonist	A ₃		Enquire
ART-1443	MRS 1754 [³H] 8-[4-(((4-cyano-[2,6- ³ H]-phenyl) carbamoylmethyl)oxy)phenyl]-1,3-di(n-propyl)xanthine M.W. 486.50	Ethanol:DMSO (3:1) 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	antagonist	A _{2b}	250 µCi / 9.25 MBq	1.311,00
ART-1256	Suramin [³H(G)] hexasodium salt C51H34N6O23S6Na6 M.W. 1429.2	Ethanol:water (1:1) 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	antagonist	P ₂	250 µCi / 9.25 MBq	414,00
ART-0884	ZM 241385 [³H] [2- ³ H]-4-(2-[7-Amino-2-(2-furyl)-[1,2,4]-triazolo-[2,3-a][1,3,5]-triazin-5-ylamino]ethyl)phenol) M.W. 337.34	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 370-1110 GBq/mmol	antagonist	A _{2A}	250 µCi / 9.25 MBq	1.431,75

Adrenergics							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BC101420	Adrenergic α_{1A} Rec., Rat	lyophilized membrane	1.13 pmol/mg total protein	receptor	α_{1A}	200 U / 4 vials	655,50
BC101520	Adrenergic α_{1B} Rec., Human	lyophilized membrane	1.00 pmol/mg total protein	receptor	α_{1B}	200 U / 4 vials	655,50
BT-ES-030-M	Adrenergic α_{2A} Rec., Human	lyophilized membrane	1 and 7.12 pmol/mg total protein	receptor	α_{2A}	200 U / vial	557,75
BT-ES-031-M	Adrenergic α_{2B} Rec., Human	lyophilized membrane	7.5 and 11.3 pmol/mg total protein	receptor	α_{2B}	200 U / vial	557,75
BT-ES-032-M	Adrenergic α_{2C} Rec., Human	lyophilized membrane	1.4 and 4.85 pmol/mg total protein	receptor	α_{2C}	200 U / vial	557,75
BC101820	Adrenergic α_{2C} Rec., Rat	lyophilized membrane	0.30 pmol/mg total protein	receptor	α_{2C}	200 U / 4 vials	655,50
BT-ES-033-M	Adrenergic β_1 Rec., Human	lyophilized membrane	3.2 and 4.5 pmol/mg total protein	receptor	β_1	200 U / vial	557,75
BT-ES-033-CF	Adrenergic cells , β_1 , Human	frozen cells	functional GPCR testing	cAMP	β_1	100 units	517,50
BT-ES-034-M	Adrenergic β_2 Rec., Human	lyophilized membrane	1.4 and 2 pmol/mg total protein	receptor	β_2	200 U / vial	557,75
BT-ES-034-CF	Adrenergic cells , β_2 , Human	frozen cells	functional GPCR testing	cAMP	β_2	100 units	517,50
BT-ES-035-M	Adrenergic β_3 Rec., Human	lyophilized membrane	37.8 and 56.6 pmol/mg total protein	receptor	β_3	200 U / vial	557,75
BT-ES-035-CF	Adrenergic cells , β_3 , Human	frozen cells	functional GPCR testing	cAMP	β_3	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0134	Dihydroalprenolol hydrochloride, levo-[propyl-1,2,3-3H] M.W. 287.8	Ethanol 1 mCi/ml	50-80 Ci/mmol 1.85-2.96 TBq/mmol	antagonist	β	250 μ Ci / 9.25 MBq	373,75
ART-0813	(-) Ephedrine-L [N-methyl-3H] M.W. 165.24	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	indirect sympathomimetic		250 μ Ci / 9.25 MBq	1.173,00
ART-0809	(-) Epinephrine-L [N-methyl-3H] M.W. 183.2	0.2 N HOAc:EtOH (9:1) 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	agonist		250 μ Ci / 9.25 MBq	983,25
ART-0880	ICI 118,551 [3H] (\pm)-1-[2,3-(Dihydro-[5- 3 H]-7-methyl-1 <i>H</i> -inden-4-yl)oxy]-3-[(1-methylethyl) amino]-2-butanol M.W. 277.41	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	antagonist	β_2	250 μ Ci / 9.25 MBq	1.374,25
ART-0382	Nisoxetine, [N-methyl-3H] M.W. 271.0	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	uptake inhibitor, NET		250 μ Ci / 9.25 MBq	868,25
ART-0172	Norepinephrine hydrochloride, DL-[7-3H] $3,4-(OH)_2C_6H_3CH(OH)CH_2NH_2.HCl$ M.W. 205.2	0.2 N Acetic acid:ethanol (9:1) 1 mCi/ml	5-15 Ci/mmol 0.185-0.555 TBq/mmol	endogenous		250 μ Ci / 9.25 MBq	483,00
ART-1430	Prazosin, [7-methoxy-3H], HCl M.W. 382.4	Ethanol:0.01N hydrochloric acid (1:1) 1 mCi/ml	70-90 Ci/mmol 2.59-3.33 TBq/mmol	antagonist	α_1, α_{2B} and α_{2C}	250 μ Ci / 9.25 MBq	1.592,75
ART-1447	SB 206606 [3H] (R,R)-4-[2-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-propyl]-[3,5- 3 H]-phenoxy-acetic acid M.W. 363.84	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	agonist	β_3	250 μ Ci / 9.25 MBq	1075,25
ART-1428	Yohimbine, [methyl-3H], HCl M.W. 390.91	Ethanol:water (1:1) 1 mCi/ml	70-90 Ci/mmol 2.59-3.33 TBq/mmol	antagonist	α_2	50 μ Ci / 1.85 MBq	868,25

Adrenomedullin							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-430-M	Adrenomedullin Receptor, Human	lyophilized membrane	9 and 13.6 pmol/mg total protein	receptor	CRLR/RAMP3	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-273	Adrenomedullin, (human) [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	enogenous	CRLR/RAMP3	50 µCi / 1.85 MBq	1.753,75
A3-AI-313	Adrenomedullin, (rat), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	enogenous	CRLR/RAMP3	50 µCi / 1.85 MBq	1.753,75
Angiotensins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-072-M	Angiotensin AT ₁ Receptor, Human	lyophilized membrane	15 and 22.6 pmol/mg total protein	receptor	AT ₁	200 U / vial	557,75
BT-ES-070-M	Angiotensin AT ₂ Receptor, Human	lyophilized membrane	0.8 and 1.2 pmol/mg total protein	receptor	AT ₂	200 U / vial	557,75
BT-ES-071-M	Angiotensin AT ₁ Receptor, Mouse	lyophilized membrane	4.3 and 6.5 pmol/mg total protein	receptor	AT ₁	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-109	Angiotensin I, (human) [3-(¹²⁵ I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.483,50
A3-AI-501	Angiotensin I/II (1-7), (human) [3-(¹²⁵ I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1.483,50
ART-0700	Angiotensin II, (5-L-Isoleucine) [tyrosyl-3,5- ³ H(N)] M.W. 1046.1	0.05M acetic acid in silanized vial 1 mCi/ml	40-80 Ci/mmol 1.48-2.96 TBq/mmol	endogenous		250 µCi / 9.25 MBq	1040,25
A3-116	Angiotensin II, (human) [3-(¹²⁵ I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.753,75
A3-127	Angiotensin II, (Sar ¹ Ile ⁸) [3-(¹²⁵ I)-Tyr ⁴]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist		50 µCi / 1.85 MBq	1.483,50
A3-129	CGP 42112A [3-(¹²⁵ I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	AT ₂	50 µCi / 1.85 MBq	1.483,50
A3-AI-200	Renin, (human) [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.483,50
Apelins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-460-M	Apelin Receptor, Human	lyophilized membrane	5.44 and 8.16 pmol/mg total protein	receptor	APJ	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-T-057	Apelin-13, (human) [(¹²⁵ I)-Tyr ⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol ¹¹	endogenous	APJ	50 µCi / 1.85 MBq	1.753,75

Benzodiazepins / GABA-ergics

Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-500-M	GABA B Receptor, Human	lyophilized membrane	55.9 and 83.9 pmol/mg total protein	receptor	GABA _{b1a/b2}	200 U / vial	557,75

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €	
ART-0207	Aminobutyric acid, γ, [2,3-³H(N)] H ₂ NCH ₂ (CH ₂) ₂ COOH M.W. 103.1	0.01 N HCl 1 mCi/ml	25-60 Ci/mmol 0.92-2.22 TBq/mmol	endogenous		250 μ Ci / 9.25 MBq	345,00	
ART-1474	7-Aminoflunitrazepam, [methyl-³H] M.W. 283.31	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	agonist	benzo-diazepine	50 μ Ci / 1.85 MBq	868,25	
ART-0523	Baclofen (-), [butyl-4-³H(N)] p-ClC ₆ H ₃ CH(CH ₂ CO ₂ H)CH ₂ NH ₂ M.W. 213.67"	Ethanol:water (7:3) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	GABA _b	250 μ Ci / 9.25 MBq	1.230,50	
ART-0576	Bicuculline methylchloride(-), [methyl-³H] M.W. 417.8	Ethanol under nitrogen 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	antagonist	GABA _a	250 μ Ci / 9.25 MBq	914,25	
ART-0553	CGP 27492, [³H] M.W. 123.1	Ethanol:water (1:1) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	GABA _b	250 μ Ci / 9.25 MBq	1.477,25	
ART-0715	CGP 54626, [³H] M.W. 444.77	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	antagonist	GABA _b	250 μ Ci / 9.25 MBq	1.259,25	
ART-0746	Chlorodiazepam, [N-methyl-³H] R05-4864 (4'- [N-methyl- ³ H]) M.W. 320.2	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	agonist	benzo-diazepine	250 μ Ci / 9.25 MBq	1000,50	
ART-0653	Diazepam, [N-methyl-³H] (Valium, Ro 5-2807) M.W. 284.74	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	agonist	benzo-diazepine	250 μ Ci / 9.25 MBq	695,75	
ART-1335	Fludiazepam, [N-methyl-³H]	Ethanol 1 mCi/ml	80-85 Ci/mmol 2.96-3.21 TBq/mmol	agonist	benzo-diazepine	50 μ Ci / 1.85 MBq	954,50	
ART-1457	Flumazenil, [N-methyl-³H] 8-Fluoro-5,6-dihydro-5-[1',1'- ³ H]-methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylic acid, ethyl ester M.W. 303.29	Ethanol:water (1:1) 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	antagonist	benzo-diazepine	250 μ Ci / 9.25 MBq	1.196,00	
ART-0577	Flunitrazepam, [methyl-³H] M.W. 313.3	Ethanol 1 mCi/ml	60-85 Ci/mmol 2.22-2.96 TBq/mmol	agonist	benzo-diazepine	250 μ Ci / 9.25 MBq	592,25	
ART-1207	L-655,708, [³H] Ethyl (S)-11,12,13,13a-Tetrahydro-7-[1',1',1'- ³ H]-methoxy-9-oxo-9H-imidazol[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate M.W. 341.36	Ethanol:water (1:1) 1 mCi/ml	45-65 Ci/mmol 1.665-2.41 TBq/mmol		GABA _a	benzo-diazepine	250 μ Ci / 9.25 MBq	1.253,50
ART-1143	Muscimol, [methylene-³H(N)] M.W. 114.1	Ethanol 1 mCi/ml	5-20 Ci/mmol 185-740 TBq/mmol	agonist	GABA _a	250 μ Ci / 9.25 MBq	1006,25	
ART-0356	Valproic acid, [2-³H], sodium salt (CH ₃ CH ₂ CH ₂) ₂ CHCO ₂ Na M.W. 166.21	Ethanol:water (4:1) 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol	anticonvulsant		250 μ Ci / 9.25 MBq	954,50	

Bombesins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-581-M	Bombesin BB1 Receptor, Human	lyophilized membrane	0.43 and 0.65 pmol/mg total protein	receptor	BB1	200 U / vial	557,75
BT-ES-582-M	Bombesin BB2 Receptor, Human	lyophilized membrane	76.5 and 114.7 pmol/mg total protein	receptor	BB2	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-115	Bombesin, [3-(¹²⁵I)-Tyr⁴]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1.483,50
Bradykinins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-091-M	Bradykinin B1 Receptor, Human	lyophilized membrane	0.31 and 0.57 pmol/mg total protein	receptor	B1	200 U / vial	557,75
BT-ES-090-M	Bradykinin B2 Receptor, Human	lyophilized membrane	52.6 and 89.2 pmol/mg total protein	receptor	B2	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0701	Bradykinin, [2,3-prolyl-3,4-³H(N)] M.W. 1060.24 ⁿ	0.2% TFA:CH ₃ CN (80:20) 1 mCi/ml	90-120 Ci/mmol 3.33-4.44 TBq/mmol	end. vasodilator		50 µCi / 1.85 MBq	862,50
A3-111	Bradykinin, [3-(¹²⁵I)-Tyr⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	end. vasodilator		50 µCi / 1.85 MBq	1.483,50
A3-AI-542	Des-Arg¹⁰-Kallidin, [¹²⁵I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	2.219,50
A3-AI-437	Leu-Bradykinin, [(¹²⁵I)Tyr⁸] (Kallidin)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1.483,50
Cannabinoids							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-110-M	Cannabinoid CB1 Receptor, Human	lyophilized membrane	5.9 and 33 pmol/mg total protein	receptor	CB ₁	200 U / vial	557,75
BC112120	Cannabinoid CB1 Receptor, Mouse	lyophilized membrane	4.88 pmol/mg total protein	receptor	CB ₁	200 U / 4 vials	655,50
BT-ES-111-M	Cannabinoid CB2 Receptor, Human	lyophilized membrane	152 and 228 pmol/mg total protein	receptor	CB ₂	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-488	AM 251, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	CB ₁	50 µCi / 1.85 MBq	1.753,75
ART-0626	Anandamide, [ethanolamine 1-³H] M.W. 347.5	Ethanol under argon 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	agonist	CB	250 µCi / 9.25 MBq	1.173,00
ART-1449	CP 55,940 [³H] (-)- <i>cis</i> -3-[2-Hydroxy-[3,5- ³ H]-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol M.W. 376.57	Ethanol:water (1:1) 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	agonist	CB	250 µCi / 9.25 MBq	1.736,50
ART-0874	(R)-(+)-Methanandamide [1-³H] ([R-(all-Z)]-N-(2-Hydroxy-1-methylethyl)-5,8,11,14-eicosatetraenamide) M.W. 361.56	Ethanol 0.1 mCi/ml	150-200 mCi/mmol 5.55-7.40 GBq/mmol	agonist	CB ₁	250 µCi / 9.25 MBq	1.477,75
ART-1448	Tetrahydrocannabinol [³H] [³ H]-1,2,8,9-Tetrahydrocannabinol / [³ H]-1,2,8,9-Tetrahydro-CBD / [³ H]-2-[[5,6- ³ H]-5-Methyl-2-([1,2- ³ H]-1-methylethyl)cyclohexyl]-5-pentyl-1,3-benzenediol M.W. 318.50	Ethanol:water (1:1) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	CB derivative	inactivates cytochrom P450	250 µCi / 9.25 MBq	1.431,75
ART-0741	Palmitoyl ethanolamide, [ethanolamine 1-³H] C ₁₈ H ₃₇ NO ₂ M.W. 299.5	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 TBq/mmol	endogenous lipid	CB ₂	250 µCi / 9.25 MBq	1.391,50

CGRP's							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-420-M	CGRP Receptor, Human	lyophilized membrane	15.2 and 22.8 pmol/mg total protein	receptor	CRLR/RAMP1	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-434	BIBN 4485, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	CGRP	50 µCi / 1.85 MBq	1.753,75
A3-110	Calcitonin, (human) [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.483,50
A3-AI-392	β-CGRP, (human) [(¹²⁵I)-Tyr⁶] β-Calcitonin Gene-Related Peptide	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.753,75
A3-AI-009	Katacalcin, [(125I)-Tyro] Calcitonin C-Terminal Flanking Peptide (human)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1483,50
Chemokines							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-133-M	Chemokine CCR2b Receptor, Human	lyophilized membrane	0.32 and 0.57 pmol/mg total protein	receptor	CCR2b	200 U / vial	557,75
BT-ES-133-AF	Chemokine CCR2b cells, Human	frozen cells	functional GPCR testing	aequorin	CCR2b	100 units	517,50
BT-ES-138-M	Chemokine CCR3 Receptor, Human	lyophilized membrane	0.4 and 0.6 pmol/mg total protein	receptor	CCR3	200 U / vial	557,75
BT-ES-140-M	Chemokine CCR7 Receptor, Human	lyophilized membrane	12.0 and 18.0 pmol/mg total protein	receptor	CCR7	200 U / vial	557,75
BT-ES-140-AF	Chemokine CCR7 cells, Human	frozen cells	functional GPCR testing	aequorin	CCR7	100 units	517,50
BT-ES-136-M	Chemokine CCR8 Receptor, Human	lyophilized membrane	Enquire	receptor	CCR8	200 U / vial	557,75
BT-ES-136-AF	Chemokine CCR8 cells, Human	frozen cells	functional GPCR testing	aequorin	CCR8	100 units	517,50
BT-ES-145-M	Chemokine CXCR2 Receptor, Human	lyophilized membrane	2.5 and 3.8 pmol/mg total protein	receptor	CXCR2	200 U / vial	557,75
BT-ES-145-AF	Chemokine CXCR2 cells, Human	frozen cells	functional GPCR testing	aequorin	CXCR2	100 units	517,50
BT-ES-142-M	Chemokine CXCR3 Receptor, Human	lyophilized membrane	7.2 and 21.2 pmol/mg total protein	receptor	CXCR3	200 U / vial	557,75
BT-ES-142-AF	Chemokine CXCR3 cells, Human	frozen cells	functional GPCR testing	aequorin	CXCR3	100 units	517,50
BT-ES-720-M	Chemokine CXCR6 Receptor, Human	lyophilized membrane	Enquire	receptor	CXCR6	200 U / vial	557,75
BT-ES-720-AF	Chemokine CXCR6 cells, Human	frozen cells	functional GPCR testing	cAMP	CXCR6	100 units	517,50
BT-ES-137-M	Chemokine CX3CR1 Receptor, Human	lyophilized membrane	0.8 and 1.2 pmol/mg total protein	receptor	CX3CR1	200 U / vial	557,75
BT-ES-137-AF	Chemokine CX3CR1 cells, Human	frozen cells	functional GPCR testing	aequorin	CX3CR1	100 units	517,50
BT-ES-148-M	Chemokine XCR1 Receptor, Human	lyophilized membrane	Enquire	receptor	XCR1	200 U / vial	557,75
BT-ES-148-AF	Chemokine XCR1 cells, Human	frozen cells	functional GPCR testing	aequorin	XCR1	100 units	517,50

Chemokines							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-492	CCL15 [¹²⁵ I] MIP-1delta, Leukotactin -1	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR1	50 µCi / 1.85 MBq	1753,75
A3-AI-533	G-CSF , [¹²⁵ I] Granulocyte Colony Stimulating Factor	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Growth Factor		50 µCi / 1.85 MBq	1753,75
A3-AI-487	CXCL 16 / SRPSOX, [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CXC chemokine	CXCR6	50 µCi / 1.85 MBq	1753,75
A3-AI-508	GRO-alpha , [(¹²⁵ I)-His]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Chemotactic Factor	CXCR1	50 µCi / 1.85 MBq	1753,75
A3-AI-511	GRO-alpha , [¹²⁵ I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Chemotactic Factor	CXCR1	50 µCi / 1.85 MBq	2.219,50
A3-AI-467	Eotaxin / CCL11, mouse [¹²⁵ I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR3	50 µCi / 1.85 MBq	2.219,50
A3-AI-347	Fractalkine / CXCL1, [¹²⁵ I] Neurotactin	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CX3C chemokine	CX3CR1	50 µCi / 1.85 MBq	1753,75
A3-AI-472	I-TAC / CXCL11, (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Chemoattractant	CXCR3	50 µCi / 1.85 MBq	1753,75
A3-AI-457	I-TAC , (mouse), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Chemoattractant	CXCR3	50 µCi / 1.85 MBq	1753,75
A3-AI-555	Interferon omega , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Chemoattractant	CXCR3	50 µCi / 1.85 MBq	1753,75
A3-AI-024	Interleukin-1 alpha , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Proinflammatory Cytokine		50 µCi / 1.85 MBq	1753,75
A3-AI-014	Interleukin-1 beta , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Proinflammatory Cytokine		50 µCi / 1.85 MBq	1753,75
A3-AI-256	Interleukin-3 , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Growth Factor		50 µCi / 1.85 MBq	1753,75
A3-138	Interleukin-6 , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Pleiotropic Cytokine		50 µCi / 1.85 MBq	1753,75
A3-AI-317	Interleukin-8 , (72 AA) [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Proinflammatory Cytokine	CXCR1/2	50 µCi / 1.85 MBq	1753,75
A3-AI-509	IP-10 (Tyr ⁷⁹⁺⁸⁰) / CXCL10, [¹²⁵ I] γ-Interferon Inducible Protein 10	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CXC chemokine	CXCR3	50 µCi / 1.85 MBq	1753,75
A3-AI-415	LIF , (human) [¹²⁵ I] Leukemia Inhibitory Factor	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Pleiotropic Cytokine		50 µCi / 1.85 MBq	1753,75
A3-AI-485	MCP1 / CCL2, (human) [¹²⁵ I] Monocyte Chemotactic Protein-1	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR2	50 µCi / 1.85 MBq	1753,75
A3-AI-537	MCP1 / CCL2, (mouse) [¹²⁵ I] Monocyte Chemoattractant Protein-1	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR2	50 µCi / 1.85 MBq	1753,75
A3-AI-558	MCP1 / CCL2, (rat) [¹²⁵ I] Monocyte Chemotactic Protein-1	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR2	50 µCi / 1.85 MBq	1753,75
A3-AI-484	MDC / CCL22, [¹²⁵ I] Macrophage Derived Chemokine	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR4	50 µCi / 1.85 MBq	1753,75
A3-AI-450	MIP-1alpha / CCL3, (human), [¹²⁵ I] Macrophage Inflammatory Protein-1alpha	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CD8/lymph.	50 µCi / 1.85 MBq	1753,75
A3-AI-420	MIP-1alpha / CCL3, (mouse), [¹²⁵ I] Macrophage Inflammatory Protein-1alpha	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CD8/lymph.	50 µCi / 1.85 MBq	1753,75

Chemokines							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-478	MIP-1delta /CCL15, (human), [¹²⁵ I] Macrophage Inflammatory Protein-1delta	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR1/CCR3	50 µCi / 1.85 MBq	1753,75
A3-AI-451	MIP-3alpha /CCL20, (human), [¹²⁵ I] Macrophage Inflammatory Protein-3alpha	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR6	50 µCi / 1.85 MBq	1753,75
A3-AI-550	MIP-3beta /CCL19, (human), [¹²⁵ I] Macrophage Inflammatory Protein-3beta	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR7	50 µCi / 1.85 MBq	1753,75
A3-AI-471	SDF-1alpha /CXCL12, (human), [¹²⁵ I] Stromal Cell Derived Factor-1alpha	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CXC chemokine	CD34 + stem cells	50 µCi / 1.85 MBq	1753,75
A3-AI-483	TARC /CCL17, (human), [¹²⁵ I] Thymus and Activation Regulated Chemokine	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	CC chemokine	CCR4	50 µCi / 1.85 MBq	1753,75
A3-AI-547	TGF-beta3 (human), [¹²⁵ I] Transforming Growth Factor beta3	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	multifunctional cytokine		50 µCi / 1.85 MBq	1753,75

Cholecystokinin and Gastrin							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-530-M	Cholecystokinin / CCK1 Receptor, Human	lyophilized membrane	8.8 and 13.2 pmol/mg total protein	receptor	CCK1	200 U / vial	557,75
BT-ES-531-M	Cholecystokinin (Gastrin) CCK2 Receptor, Human	lyophilized membrane	138 and 19.6 pmol/mg total protein	receptor	CCK2	200 U / vial	557,75

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-531	(Tyr²⁸, Nle³¹) Cholecystokinin-33 (25-33) , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	CCK2	50 µCi / 1.85 MBq	1483,50
A3-AI-376	CCK 8 peptide , [(¹²⁵ I)Tyr ⁹] (sulfated)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1483,50
A3-AI-194	CCK 8 peptide , [(¹²⁵ I)Tyr ⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1483,50
A3-AI-225	(Leu¹⁵) Gastrin , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue		50 µCi / 1.85 MBq	1483,50

Cholinergics							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-210-M	Muscarinic M1 Receptor, Human	lyophilized membrane	1.4 and 7.5 pmol/mg total protein	receptor	M ₁	200 U / vial	557,75
BC102420	Muscarinic M1 Receptor, Mouse	lyophilized membrane	0.76 pmol/mg total protein	receptor	M ₁	200 U / 4 vials	570,00
BT-ES-211-M	Muscarinic M2 Receptor, Human	lyophilized membrane	0.85 and 1.44 pmol/mg total protein	receptor	M ₂	200 U / vial	557,75
BC102620	Muscarinic M2 Receptor, Pig	lyophilized membrane	3.34 pmol/mg total protein	receptor	M ₂	200 U / 4 vials	655,50
BT-ES-212-M	Muscarinic M3 Receptor, Human	lyophilized membrane	2.9 and 6.7 pmol/mg total protein	receptor	M ₃	200 U / vial	557,75
BT-ES-213-M	Muscarinic M4 Receptor, Human	lyophilized membrane	2.9 and 7.5 pmol/mg total protein	receptor	M ₄	200 U / vial	557,75
BT-ES-214-M	Muscarinic M5 Receptor, Human	lyophilized membrane	6.16 and 9.24 pmol/mg total protein	receptor	M ₅	200 U / vial	557,75
BT-ES-760-M	Nicotinic Receptor, Human	lyophilized membrane	2.0 and 3.0 pmol/mg total protein	receptor		200 U / vial	557,75

Cholinergics							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0317	Acetylcholine iodide, [methyl-³H] CH ₃ COOCH ₂ CH ₂ N(CH ₃) ₃ I M.W. 273.1	Ethanol:water (9:1) 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	endogenous		250 µCi / 9.25 MBq	391,00
ART-0787	(±)4-Aminobenzovesamicol, [3',4'-³H] (RS) M.W. 394.15	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	inhibitor	acetylcholine transporter	250 µCi / 9.25 MBq	1.345,50
ART-1369	(±) Epibatidine, [5,6-bicycloheptyl-³H] M.W. 208.7	Ethanol under argon 1 mCi/ml	30-70 Ci/mmol 1.11-2.59 TBq/mmol	agonist	nicotinic	250 µCi / 9.25 MBq	1.184,50
ART-1442	Ibogaine, [(G)-³H] M.W. 364.89	Ethanol 1 mCi/ml	5-15 Ci/mmol 0.185-0.55 GBq/mmol	antagonist	nicotinic		Enquire
ART-0882	Methyllycaconitine [³H] ([1α,4(S),6β,14α,16β]-20-Ethyl-1,6,14,16-tetramethoxy-4-[[[2-(3[3-3H]-[3-3H]-methyl-2,5-dioxo-1-pyrrolidinyl)benzoyl]oxy]methyl]aconitane-7,8-diol) M.W. 682.8	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	antagonist	α7AChR	250 µCi / 9.25 MBq	1.374,25
ART-0385	Nicotine, DL-[N-methyl-³H] M.W. 162.2	Ethanol 1 mCi/ml	30-85 Ci/mmol 1.11-3.15 TBq/mmol	agonist	nicotinic	250 µCi / 9.25 MBq	488,75
ART-0151	Nicotine, L-[N-methyl-³H] M.W. 162.2	Ethanol 1 mCi/ml	30-85 Ci/mmol 1.11-3.15 TBq/mmol	active enantiomer	nicotinic	250 µCi / 9.25 MBq	741,75
ART-0314	Scopolamine, [N-methyl-³H] hydrochloride C ₁₇ H ₂₁ NO ₄ HCl M.W. 303.35	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	antagonist	muscarinic	50 µCi / 1.85 MBq	1.339,75

Corticotropin Releasing Factors (CRF)							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-152-M	CRF1 Receptor, Human	lyophilized membrane	92.4 and 138.6 pmol/mg total protein	receptor	CRF1	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-532	Antisauvagine 30, [¹²⁵I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	CRF2	50 µCi / 1.85 MBq	2.219,50
A3-AI-53	Antisauvagine 30, [(¹²⁵I)-His]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	CRF2	50 µCi / 1.85 MBq	1.753,75
A3-AI-438	Corticotropin Releasing Factor, CRF (human/rat), [(¹²⁵I)Tyr⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1483,50
A3-AI-327	Corticotropin Releasing Factor, CRF (ovine), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1483,50
A3-AI-279	Sauvagine, (frog), [(¹²⁵I)-Tyr⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	non selective	50 µCi / 1.85 MBq	1483,50
A3-AI-426	Sauvagine, (human), [¹²⁵I)-Tyr⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	non selective	50 µCi / 1.85 MBq	1483,50
A3-AI-431	Astressin, [(¹²⁵I)D-Tyr¹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	non selective	50 µCi / 1.85 MBq	1483,50

Dopaminergics							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-172-M	Dopamine D1 Receptor, Human	lyophilized membrane	3.5 and 8.4 pmol/mg total protein	receptor	D ₁	200 U / vial	557,75
BT-ES-172-AF	Dopamine D1 cells, Human	frozen cells	functional GPCR testing	cAMP	D ₁	100 units	517,50
BC104320	Dopamine D2 Receptor, Human	lyophilized membrane	8.35 pmol/mg total protein	receptor	D ₂	200 U / 4 vials	655,50
BC104420	Dopamine D2 Receptor, Mouse	lyophilized membrane	12.3 pmol/mg total protein	receptor	D ₂	200 U / 4 vials	655,50
BT-ES-173-M	Dopamine D3 Receptor, Human	lyophilized membrane	10.1 and 14.1 pmol/mg total protein	receptor	D ₃	200 U / vial	557,75
BC104620	Dopamine D4 Receptor, Human	lyophilized membrane	8.35 pmol/mg total protein	receptor	D ₄	200 U / 4 vials	655,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0808	R(-)-Apomorphine, [N-methyl-³H] hydrochloride M.W. 303.7	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	agonist	DA	250 µCi / 9.25 MBq	1132,75
ART-0519	Clozapine, [N-methyl-³H] M.W. 326.45	Ethanol under nitrogen 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	antagonist	D ₄	250 µCi / 9.25 MBq	914,25
ART-0651	Cocaine, [N-methyl-³H] C ₁₇ H ₂₁ NO ₄ M.W. 339.82	Ethanol under nitrogen 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	reuptake inhibitor		250 µCi / 9.25 MBq	1.173,00
A3-AI-062	Dihydroergocryptine, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	DA	50 µCi / 1.85 MBq	1.753,75
ART-0235	Dihydroxyphenylalanine, L-3,4-[ring 2,5,6-³H] (L-Dopa) 3,4-(OH) ₂ C ₆ H ₃ CH ₂ CH(NH ₂)COOH M.W. 197.2	0.2N HOAc:EtOH (9:1) 1 mCi/ml	20-60 Ci/mmol 0.74-2.22 TBq/mmol	precursor	DA	250 µCi / 9.25 MBq	914,25
ART-1401	FLB-457, [methyl-³H] C ₁₆ H ₂₃ BrN ₂ O ₃ M.W. 371.27	Ethanol 1 mCi/ml	60-80 Ci/mmol 1.85-2.96 TBq/mmol	antagonist	D ₂	50 µCi / 1.85 MBq	914,25
ART-1198	MFZ 2-12, [³H] M.W. 328.2	Ethanol 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	transporter	DAT	50 µCi / 1.85 MBq	649,75
ART-0849	Methyl-4-phenylpyridinium acetate, N-[methyl-³H]-MPP(+) M.W. 229.3	Ethanol 1 mCi/ml	80-85 Ci/mmol 2.96-3.14 TBq/mmol	neurotoxin	uptake	250 µCi / 9.25 MBq	345,00
ART-0150	Methyl-4-phenylpyridinium iodide, N-[methyl-³H]-MPP(+) M.W. 229.3	Ethanol:water (1:1) 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	neurotoxin	uptake	250 µCi / 9.25 MBq	327,75
ART-0136	Methyl-4-phenyl 1,2,3,6-tetrahydro-pyridine, 1-[methyl-³H] MPTP M.W. 173.3	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	precursor	uptake	250 µCi / 9.25 MBq	373,75
ART-0660	Methylspiperone, [N-methyl-³H] M.W. 409.5	Ethanol under argon 1 mCi/ml	70-87 Ci/mmol 2.59-3.21 TBq/mmol	antagonist	D ₂	250 µCi / 9.25 MBq	868,25
ART-0811	R(-)-N-Propylnorapomorphine [N-propyl-³H] hydrochloride M.W. 343.9	Ethanol 1 mCi/ml	30-60 Ci/mmol 2.59-3.22 TBq/mmol	agonist	D ₂	50 µCi / 1.85 MBq	868,25
ART-0805	(S)-Raclopride, [methoxy-³H] M.W. 347.7	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	antagonist	D ₂	250 µCi / 9.25 MBq	822,25
ART-0521	SCH 23390, [N-methyl-³H] M.W. 287.8	Ethanol under argon 1 mCi/ml	70-85 Ci/mmol 2.59-3.15 TBq/mmol	antagonist	D ₁	250 µCi / 9.25 MBq	695,75
ART-0425	Tyramine hydrochloride, [ring-3,5-³H] <i>p</i> -HOC ₆ H ₄ CH ₂ CH ₂ NH ₂ ·HCl M.W. 173.65	0.01 N HCl under nitrogen 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	transporter		250 µCi / 9.25 MBq	408,25

Endothelins							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-320-M	Endothelin ET_A Receptor, Human	lyophilized membrane	124.8 and 187.2 pmol/mg total protein	receptor	ET _A	200 U / vial	557,75
BT-ES-321-M	Endothelin ET_B Receptor, Human	lyophilized membrane	7.3 and 10.9 pmol/mg total protein	receptor	ET _B	200 U / vial	557,75
BT-ES-321-M	Endothelin ET_B cells , Human	frozen cells	functional GPCR testing	aequorin	ET _B	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-337	Big-Endothelin-1, (fragment 22-38) [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-084	Big-Endothelin-1, (human), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-088	Big-Endothelin-1, (porcine), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-288	Big-Endothelin-1, (rat, 1-39), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-154	Big-Endothelin-2, [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-155	Big-Endothelin-3, [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-AI-307	Big-Endothelin-3, (rat), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	precursor		50 µCi / 1.85 MBq	1.483,50
A3-118	Endothelin-1, (human/porcine), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	natural ligand	50 µCi / 1.85 MBq	1.483,50
A3-143	Endothelin-1, (human), (Ala^{1,3,11,15}) [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	ET _B	50 µCi / 1.85 MBq	1.483,50
A3-130	Endothelin-2, (human), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	natural ligand	50 µCi / 1.85 MBq	1.483,50
A3-AI-068	Endothelin-3, (human), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	natural ligand	50 µCi / 1.85 MBq	1.753,75
A3-123	Endothelin-3, (rat), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol [†]	endogenous	natural ligand	50 µCi / 1.85 MBq	1.753,75
A3-124	Sarafotoxin S6b, [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist		50 µCi / 1.85 MBq	1.753,75
A3-157	Sarafotoxin S6c, [3-(¹²⁵I)-His]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	ET _B	10 µCi / 0.37 MBq	1.753,75

Enzyme Inhibitors							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0803	Deprenyl hydrochloride, [N-methyl-³H] (Selegiline hydrochloride, [N-methyl- ³ H]) M.W. 223.8	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	inhibitor	MAO-B	250 µCi / 9.25 MBq	2.001,00
ART-0762	Genistein, [³H(G)], (4',5,7-trihydroxyisoflavone) M.W. 270.23	Ethanol under argon 1 mCi/ml	1-5 Ci/mmol 37-185 GBq/mmol	inhibitor	protein tyrosin kinase	50 µCi / 1.85 MBq	695,75
ART-0794	Ketoconazole, [³H(G)] M.W. 531.44	Ethanol 1 mCi/ml	1-5 Ci/mmol 37-185 GBq/mmol	inhibitor	CYP 450	250 µCi / 9.25 MBq	1.299,50
ART-0315	Mevalonolactone, RS-[5-³H] M.W. 130.1	Ethanol 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	precursor	RAS farnesylation	250 µCi / 9.25 MBq	235,75
ART-0629	Rolipram, [6-³H] C ₁₆ H ₂₁ NO ₃ M.W. 275.35	Ethanol 1 mCi/ml	20-30 Ci/mmol 0.74-1.11 TBq/mmol	inhibitor	PDE IV	250 µCi / 9.25 MBq	868,25
ART-0490	Sphingosine, D-erythro-[3-³H] <i>trans</i> -D-erythro-2-Amino-4-octadecene-1,3-diol M.W. 299.5	Ethanol under nitrogen 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	inhibitor	protein kinase C	250 µCi / 9.25 MBq	2.087,25
ART-0341	Theophylline, [8-³H] M.W. 180.17	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 TBq/mmol	inhibitor	cyclic phosphodiesterase	250 µCi / 9.25 MBq	741,75
GABA / Glycine Receptor							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-500-M	GABA B Receptor, Human	lyophilized membrane	55.9 and 83.9 pmol/mg total protein	receptor	GABA _{b1a/b2}	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0715	CGP 54626, [³H] M.W. 444.77	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	antagonist	GABA _b	250 µCi / 9.25 MBq	1.259,25
ART-1303	Gabapentin, [³H] 1-(Amino-[³ H]-methyl)-[2,3,5,6- ³ H]-cyclohexaneacetic acid M.W. 171.20	Ethanol:water (1:1) solution 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	see Ion Channel		250 µCi / 9.25 MBq	1.196,00
ART-0161A	Glycine, [2-³H] H ₂ NCH ₂ COOH M.W. 75.1	Ethanol:water (2:98) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous	NMDA	250 µCi / 9.25 MBq	155,25
ART-1210	P4MPA, [³H] [Methyl-3,4- ³ H]-piperidin-4-yl-phosphinic acid M.W. 163.15	Ethanol:water (1:1) 1 mCi/ml	20-50 Ci/mmol 0.74-1.85 TBq/mmol	antagonist	GABA _c	250 µCi / 9.25 MBq	1.063,75
ART-0300	Taurine, [2-³H] H ₂ NCH ₂ CH ₂ SO ₂ OH M.W. 125.1	0.01 N HCl 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	partial agonist	glycine	250 µCi / 9.25 MBq	437,00
ART-0728	Serine, D-[3-³H] HOCH ₂ CH(NH ₂)CO ₂ OH M.W. 105.1	Ethanol:water (2:98) 1 mCi/ml	15-40 Ci/mmol 0.55-1.48 TBq/mmol	glycine agonist	NMDA	250 µCi / 9.25 MBq	782,00
ART-0246	Serine, L-[3-³H] HOCH ₂ CH(NH ₂)COOH M.W. 105.1	0.01 N HCl 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous agonist	glycine	250 µCi / 9.25 MBq	155,25
ART-0848	Strychnine, [³H(G)] M.W. 334.4	Ethanol under nitrogen 1 mCi/ml	15-40 Ci/mmol 0.55-1.48 TBq/mmol	antagonist	glycine	250 µCi / 9.25 MBq	695,75

Galanins							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-510-M	Galanin GalR1 Receptor, Human	lyophilized membrane	4 and 6 pmol/mg total protein	receptor	GalR1	200 U / vial	557,75
BT-ES-510-CF	Galanin cells , Human	frozen cells	functional GPCR testing	cAMP	GalR1	100 units	517,50
BT-ES-511-M	Galanin GalR2 Receptor, Human	lyophilized membrane	75.2 and 112.8 pmol/mg total protein	receptor	GalR2	200 U / vial	557,75
BC105620	Galanin GalR3 Receptor, Human	lyophilized membrane	0.79 pmol/mg total protein	receptor	GalR3	200 U / 4 vials	655,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-154	Galanin , (human), [¹²⁵ I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	natural ligand	50 µCi / 1.85 MBq	2.219,50
A3-AI-316	Galanin , (human), [³ -(¹²⁵ I)-Tyr ⁹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	natural ligand	50 µCi / 1.85 MBq	1.483,50
A3-153	Galanin , (porcine), [³ -(¹²⁵ I)-Tyr ²⁶]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol"	endogenous	natural ligand	50 µCi / 1.85 MBq	1.483,50
Ghrelins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-410-M	Ghrelin Receptor, Human	lyophilized membrane	22.2 and 33.2 pmol/mg total protein	receptor	GHS-R	200 U / vial	557,75
BT-ES-510-AF	Ghrelin cells , Human	frozen cells	functional GPCR testing	aequorin	GHS-R	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-397	Ghrelin , (human), [(¹²⁵ I)His]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GHS	50 µCi/1.85 MBq	1.735,75
A3-AI-441	Ghrelin , (human), [(¹²⁵ I)Tyr ⁴]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GHS	50 µCi/1.85 MBq	1.483,50
A3-AI-443	Ala-Hexarelin , [¹²⁵ I-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	GHRP-analogue	GHS	50 µCi / 1.85 MBq	1.483,50
Glutamate Receptor Compounds, Ionotropic / Excitatory Amino Acids							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0539	(S)-(-)-5-Fluorowillardiine , [³ H] (S)-(-)-a-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)pyridine-[2,3- ³ H]propanoic acid M.W. 217.15	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	agonist	AMPA	250 µCi / 9.25 MBq	782,00
ART-0875	Homoquinolinic acid , [5,6- ³ H] M.W. 181.15"	Ethanol:water (1:1) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	NMDA	250 µCi / 9.25 MBq	1.311,00
ART-1442	Ifenprodil , [³ H] 2-(4-Benzylpiperidino)-1-(4-hydroxy-[3,5- ³ H]-phenyl)-1-propanol M.W. 325.44	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	antagonist	NMDA poly-amine side δ ligand	250 µCi / 9.25 MBq	1.017,75
ART-0881	L-689,560 , [³ H] trans-2-Carboxy-5,7-dichloro-4-[4'- ³ H]-phenylaminocarbonyl-amino-1,2,3,4-tetrahydroquinoline M.W. 380.23	Ethanol 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	antagonist	NMDA Glycine	250 µCi / 9.25 MBq	1.374,25
ART-0661	(+)-MK-801 , [³ H] [³ H]-Dizocilpine / (5S,10R)-(+)-5-Methyl-L-[3,7- ³ H]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine M.W. 221.30	Ethanol:water (1:1) 1 mCi/ml	15-40 Ci/mmol 0.55-1.48 TBq/mmol	antagonist	NMDA	250 µCi / 9.25 MBq	782,00

Glutamate Receptor Compounds, Ionotropic / Excitatory Amino Acids

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-1391	PhTx-56, [³H] (philanthotoxin analogue) M.W. 434.32	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	antagonist	AMPA	50 µCi / 1.85 MBq	914,25
ART-0471	Spermine tetrahydrochloride [terminal methylene-³H] $\text{NH}_2\text{CH}_2(\text{CH}_2)_2\text{NH}(\text{CH}_2)_4\text{NH}(\text{CH}_2)_2\text{CH}_2\text{NH}_2 \cdot 4\text{HCl}$ M.W. 348.2	Ethanol:water (9:1) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	modulator	NMDA	1 mCi / 37 MBq	1.000,50

Glutamate Receptor Compounds, Metabotropic / Excitatory Amino Acids

Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BC106820	Glutamate mGluR3 Receptor, Human	lyophilized membrane	1.99 pmol/mg total protein	receptor	mGluR ₃	200 U / 4 vials	655,50
BT-ES-555-M	Glutamate mGluR5 Receptor, Human	lyophilized membrane	2.6 and 3.9 pmol/mg total protein	receptor	mGluR ₅	200 U / vial	557,75

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0535	(D)-AP5-[³H] , D(-)-2-Amino-5-phosphono-[4,5- ³ H]-pentanoic acid M.W. 197.13	Ethanol:water (1:1) 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	antagonist	NMDA	250 µCi / 9.25 MBq	782,00
ART-0534	(L)-AP4-[³H] , L(+)-2-Amino-4-phosphono-[2,3- ³ H]-butyric acid M.W. 183.1	Ethanol:water (1:1) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	group III mGlu	250 µCi / 9.25 MBq	914,25
ART-0211	Aspartic acid, L-[2,3-³H] $\text{HOOCCH}_2\text{CH}_2(\text{NH}_2)\text{COOH}$ M.W. 133.1	2% aqueous ethanol 1 mCi/ml	10-25 Ci/mmol 0.37-0.925 TBq/mmol	agonist	NMDA	250 µCi / 9.25 MBq	224,25
ART-0883	CPPG, [³H] (RS)-α-Cyclopropyl-[3- ³ H]-4-phosphonophenylglycine M.W. 271.21	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	antagonist	group II/III mGlu	250 µCi / 9.25 MBq	1.132,75
ART-1206	DCG IV, [³H] (2S,2'R,3'R)-2-(1'-3H,2',3'-Dicarboxycyclopropyl)glycine M.W. 203.15	Ethanol:water (1:1) 1 mCi/ml	10-25 Ci/mmol 0.370-0.925 TBq/mmol	agonist	group II mGlu	250 µCi / 9.25 MBq	1.495,00
ART-1450	(S)-3,4-DCPG, [³H] (S)-3,4-[5- ³ H]-Dicarboxyphenylglycine M.W. 239.18	Ethanol:water (1:1) 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	agonist	mGlu _{8a}	250 µCi / 9.25 MBq	1.525,50
ART-0132	Glutamic acid, L-[2,3,4-³H] $\text{HOOCCH}_2\text{CH}_2\text{CH}(\text{NH}_2)\text{COOH}$ M.W. 147.1	2% aqueous ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous		250 µCi / 9.25 MBq	155,25
ART-0232	Glutamic acid, D-[2,3,4-³H] $\text{HOOCCH}_2\text{CH}_2\text{CH}(\text{NH}_2)\text{COOH}$ M.W. 147.1	0.01 N HCl 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	less active agonist		250 µCi / 9.25 MBq	546,25
ART-0149	Glutamine, L-[2,3,4-³H] $\text{H}_2\text{NCO}(\text{CH}_2)_2\text{CH}(\text{NH}_2)\text{COOH}$ M.W. 146.2	Ethanol:water (1:99) 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous		250 µCi / 9.25 MBq	201,25
A3-156	Joro-Spider-Toxin, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	AMPA	50 µCi / 1.85 MBq	1.896,35
ART-0133	Kainic acid, [vinylidene-³H] M.W. 213.2	Ethanol:water (2:98) under argon 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	kainate	250 µCi / 9.25 MBq	1.282,25
ART-1503	Kynurenic acid, [5,7-³H] M.W. 189.17	Ethanol:water (1:1) 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	broad spectrum antagonist	EAA	50 µCi / 1.85 MBq	523,25
ART-1439	LY 341495, [³H] (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-[2,7- ³ H]xanth-9-yl)propanoic acid M.W. 353.37	Ethanol:water (1:1) 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	antagonist	group II mGlu	250 µCi / 9.25 MBq	1.610,00

<i>Glutamate Receptor Compounds, Metabotropic / Excitatory Amino Acids</i>							
<i>Cat.No</i>	<i>Compound</i>	<i>Solvent</i>	<i>Spec. Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
ART-1209	MPEP, [³H] 2-Methyl-6-([3,5- ³ H] phenylethynyl) pyridine M.W. 193.24	Ethanol:water (1:1) 1 mCi/ml	25-45 Ci/mmol 0.925-1.665 TBq/mmol	antagonist	mGlu ₅	250 µCi / 9.25 MBq	1.794,00
ART-1161	N-Methyl-D-aspartic acid, [methyl-³H] (NMDA) HO ₂ CCH ₂ CH(NHCH ₃)CO ₂ H M.W. 147.13	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	prototypic NMDA		250 µCi / 9.25 MBq	695,75
ART-0879	SYM 2081, [³H] (2S,4R)-[4- ³ H]-4-[³ H] Methylglutamic acid M.W. 161.16	Ethanol:water (1:1) 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	antagonist	kainate	250 µCi / 9.25 MBq	741,75
<i>Growth Factors</i>							
<i>Cat.No</i>	<i>Compound</i>	<i>Solvent</i>	<i>Spec. Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
A3-AI-566	Epidermal Growth Factor, (EGF), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	EGFR	50 µCi / 1.85 MBq	1.753,75
A3-AI-361	Growth Hormone, (canine), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.753,75
A3-119	Insulin-like Growth Factor-I, IGF I, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-128	Insulin-like Growth Factor-II, IGF II, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-AI-245	Insulin-like Growth Factor Binding Protein 2, [¹²⁵I] IGFBP-2	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-155	Insulin-like Growth Factor Binding Protein 3, [¹²⁵I] IGFBP-3	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-AI-129	Insulin-like Growth Factor Binding Protein 4, [¹²⁵I] IGFBP-4	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-AI-130	Insulin-like Growth Factor Binding Protein 5, [¹²⁵I] IGFBP-5	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
A3-AI-131	Insulin-like Growth Factor Binding Protein 6, [¹²⁵I] IGFBP-6	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	IGFR	50 µCi / 1.85 MBq	1.753,75
<i>Histaminergics</i>							
<i>Cat.No</i>	<i>Compound</i>	<i>Preparation</i>	<i>Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
BT-ES-390-M	Histamine H1 Receptor, Human	lyophilized membrane	7.5 and 17.14 pmol/mg total protein	receptor	H ₁	200 U / vial	557,75
BT-ES-390-AF	Histamine H1 cells , Human	frozen cells	functional GPCR testing	aequorin	H ₁	100 units	517,50
BT-ES-391-M	Histamine H2 Receptor, Human	lyophilized membrane	10.4 and 15.6 pmol/mg total protein	receptor	H ₂	200 U / vial	557,75
BT-ES-391-CF	Histamine H2 cells , Human	frozen cells	functional GPCR testing	cAMP	H ₂	100 units	517,50
BC106220	Histamine H2 Receptor, Rat	lyophilized membrane	2.28 pmol/mg total protein	receptor	H ₂	200 U / 4 vials	655,50
BT-ES-392-M	Histamine H3 Receptor, Human	lyophilized membrane	3.8 and 7.25 pmol/mg total protein	receptor	H ₃	200 U / vial	557,75
BT-ES-392-CF	Histamine H3 cells , Human	frozen cells	functional GPCR testing	cAMP	H ₃	100 units	517,50
BT-ES-393-M	Histamine H4 Receptor, Human	lyophilized membrane	1.4 and 7.12 pmol/mg total protein	receptor	H ₄	200 U / vial	557,75

Histaminergics							
Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0234	Histidine, L-[ring-2,5-³H] C ₃ H ₃ N ₂ CH ₂ CH(NH ₂)COOH M.W. 155.2	2% Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	precursor of histamine		250 µCi / 9.25 MBq	130,00
ART-1431	Mepyramine, [methyl-³H] pyrilamine M.W. 285.4	Ethanol:water (1:1) 1 mCi/ml	20-30 Ci/mmol 0.74-1.11 TBq/mmol	antagonist	H ₁		Enquire
ART-1435	Methylhistamine, dihydrochloride, N-α-[methyl-³H] M.W. 198.1	Ethanol:water (1:1) 1 mCi/ml	45-90 Ci/mmol 1665-3330 GBq/mmol	agonist	H ₃	25 µCi / 925 MBq	310,00
Imidazolines							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0877	RS45041-190, [³H] C ₁₁ H ₁₂ ClN ₃ M.W. 258.15	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	ligand	I ₂		Enquire
ART-0608	Agmatine, L [2,3,4,5-³H] H ₂ NC(NH)NH(CH ₂) ₃ CH ₂ NH ₂ M.W. 130.0	0.01 N HCl 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	endogenous		250 µCi / 9.25 MBq	1.210,00
Ion Channel Modulators							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0714	Caffeine, [1-methyl-³H] M.W. 194.2	Ethanol under argon 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	inducer	Ca ²⁺ release (SR)	250 µCi / 9.25 MBq	1.391,50
A3-151	Charybdotoxin, [3-(¹²⁵I)Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	K ⁺ channel	50 µCi / 1.85 MBq	1.483,50
ART-0462	Emopamil, [N-methyl-³H] M.W. 334.51	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	antagonist	Ca ²⁺ channel	250 µCi / 9.25 MBq	1.822,75
ART-1303	Gabapentin, [³H] 1-(Amino-[³ H]-methyl)-[2,3,5,6- ³ H]-cyclohexaneacetic acid M.W. 171.2	Ethanol:water (1:1) solution 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	Voltage-gated Ca ²⁺ channel	α ₂ δ subunit	250 µCi / 9.25 MBq	1.196,00
ART-0810	Lidocaine, [N-ethyl-1-³H] N-ethyl bromide, quaternary salt, M.W. 343.3	Ethanol:water (1:1) 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	antiarrhythmic	Na ⁺ channel	50 µCi / 1.85 MBq	1.040,75
ART-0452	Quinidine, [9-³H] M.W. 324.4	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol	antagonist/blocker	Na ⁺ channel	250 µCi / 9.25 MBq	914,25
ART-0451	Quinine, [9-³H] M.W. 324.4 ⁿ	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol	antagonist/blocker	K ⁺ channel	250 µCi / 9.25 MBq	914,25
ART-0711	Minoxidil, [piperyl-3,4-³H] M.W. 209.25	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	activator	K ⁺ channel	250 µCi / 9.25 MBq	1.431,75
ART-0667	Verapamil hydrochloride [N-methyl ³H] M.W. 491.0	Ethanol 1 mCi/ml	60-85 Ci/mmol (2.22-3.15 TBq/mmol)	antagonist	Ca ²⁺ channel L-type	250 µCi / 9.25 MBq	868,25
Leukotrienes							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-340-M	Leukotriene LTB₄R1 Receptor, Human	lyophilized membrane	41.1 and 61.7 pmol/mg total protein	receptor	LTB ₄ R1	200 U / vial	557,75
BT-ES-470-M	Leukotriene CysLT1 Receptor, Human	lyophilized membrane	5.1 and 7.7 pmol/mg total protein	receptor	CysLT1	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0657	Leukotriene B₄, [5,6,8,9,11,12,14,15-³H] C ₂₀ H ₃₂ O ₄ M.W. 336.47	Ethanol under argon in silanized vial 1 mCi/ml	160-240 Ci/mmol 5.92-8.88 TBq/mmol	agonist		25 µCi / 925 kBq	1.955,00

MCH, Melanin Concentrating Hormone							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-370-M	MCH1 Receptor, Human	lyophilized membrane	1.22 and 7.95 pmol/mg total protein	receptor	MCH ₁	200 U / vial	557,75
BT-ES-370-AF	MCH1 cells , Human	frozen cells	functional GPCR testing	aequorin	MCH ₁	100 units	517,50
BT-ES-371-M	MCH2 Receptor, Human	lyophilized membrane	Enquire	receptor	MCH ₂	200 U / vial	557,75
BT-ES-371-AF	MCH2 cells , Human	frozen cells	functional GPCR testing	aequorin	MCH ₂	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-370	Melanin Concentrating Hormone, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	MCH	50 µCi / 1.85 MBq	1.483,50
A3-AI-339	(Phe¹³)-Melanin Concentrating Hormone, [(¹²⁵I)Tyr¹⁹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	MCH	50 µCi / 1.85 MBq	1.483,50
Melanocortin Receptors							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-193-M	Melanocortin MC3 Receptor, Human	lyophilized membrane	1.1 and 1.6 pmol/mg total protein	receptor	MC ₃	200 U / vial	557,75
BT-ES-193-CF	Melanocortin MC3 Receptor, Human cells	frozen cells	functional GPCR testing	cAMP	MC ₃	100 units	517,50
BT-ES-190-M	Melanocortin MC3 Receptor, Mouse	lyophilized membrane	Enquire	receptor	MC ₃	200 U / vial	557,75
BT-ES-191-M	Melanocortin MC4 Receptor, Human	lyophilized membrane	16 and 91.6 pmol/mg total protein	receptor	MC ₄	200 U / vial	557,75
BT-ES-191-CF	Melanocortin MC4 cells , Human	frozen cells	functional GPCR testing	cAMP	MC ₄	100 units	517,50
BT-ES-194-M	Melanocortin MC5 Receptor, Human	lyophilized membrane	2.5 and 3.8 pmol/mg total protein	receptor	MC ₅	200 U / vial	557,75
BT-ES-194-CF	Melanocortin MC5 cells , Human	frozen cells	functional GPCR testing	cAMP	MC ₅	100 units	517,50
BT-ES-192-M	Melanocortin MC5 Receptor, Mouse	lyophilized membrane	1.25 and 1.87 pmol/mg total protein	receptor	MC ₅	200 U / vial	557,75
Melatonins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-620-M	Melatonin MT1 Receptor, Human	lyophilized membrane	8.67 and 12.97 pmol/mg total protein	receptor	MT ₁	200 U / vial	557,75
BT-ES-621-M	Melatonin MT2 Receptor, Human	lyophilized membrane	0.464 and 0.699 pmol/mg total protein	receptor	MT ₂	200 U / vial	557,75
BT-ES-621-AF	Melatonin MT2 cells , Human	frozen cells	functional GPCR testing	aequorin	MT ₂	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0424	Acetyl-5'-methoxytryptamine, N-[methoxy-³H], melatonin M.W. 232.3	Ethanol under nitrogen 1 mCi/ml	60-85 Ci/mmol 2.22-2.96 TBq/mmol	agonist		250 µCi / 9.25 MBq	822,25
ART-1504	Melatonin, [2-³H] M.W. 232.3	Ethanol under nitrogen 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	agonist			Enquire

Miscellaneous

Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
ART-1458	Amitriptyline hydrochloride, [N-methyl-³H] Antidepressant M.W. 277.41	Ethanol 1 mCi/ml	60-85 Ci/mmol 2.22-2.96 TBq/mmol	antagonist	H ₁	50 µCi / 1.85 MBq	868,25
ART-1452	Amphetamine, D-[ring-2,3,5-³H] hydrochloride M.W. 177.26	Ethanol 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	blocks catecholamine reuptake		50 µCi / 1.85 MBq	868,25
ART-1453	Amphetamine, L-[ring-2,3,5-³H] hydrochloride M.W. 177.26	Ethanol 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	less active enantiomer		50 µCi / 1.85 MBq	868,25
ART-1507	Amphotericin B, [(G)-³H]	Ethanol 1 mCi/ml	5-15 Ci/mmol 0.185-0.555 TBq/mmol	antifungal		50 µCi / 1.85 MBq	868,25
ART-1473	Cyclopamine, [3-³H] M.W. 411.62	Ethanol 1 mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	Hedgehog signaling pathway inhibitor		50 µCi / 1.85 MBq	868,25
ART-0801	Doxepin hydrochloride, [N-methyl-³H] Antidepressant M.W. 315.8	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	antagonist	H ₁	50 µCi / 1.85 MBq	1.219,00
A3-AI-380	Epoetin alpha, [¹²⁵I] (EPO=Erythropoietin),	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	erythrocyte stimulant	50 µCi / 1.85 MBq	1.753,75
A3-AI-301	Echistatin, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	inhibitor of platelet aggregation	Disintegrin	50 µCi / 1.85 MBq	1.753,75
ART-1463	Ezetimibe, [(G)-³H] M.W. 409.4"	Ethanol 1 mCi/ml	1-5 Ci/mmol 37-185 GBq/mmol	inhibitor	cholesterol absorption	250 µCi / 9.25 MBq	523,25
A3-AI-238	Fibrinogen (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	platelet aggregation	50 µCi / 1.85 MBq	1.753,75
A3-AI-211	Fibronectin (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	FNR	50 µCi / 1.85 MBq	1.753,75
A3-AI-248	Flagellin, [(¹²⁵I)-Tyr⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	pathogenic	TLR5	50 µCi / 1.85 MBq	1.483,50
ART-1113	IDN-5109, [³H] (SB-T-101131-³H) M.W. 871.9	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	Taxane	anti-tumor agent	250 µCi / 9.25 MBq	649,75
ART-1159	IDN-5390, [³H] C ₄₁ H ₅₇ NO ₁₄ M.W. 787.9	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	Taxane	anti-angiogenic	250 µCi / 9.25 MBq	1.040,75
A3-AI-367	Methotrexate-HSA, [¹²⁵I] Albumin-coupled Methotrexate	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antimetabolite	dihydrofolate reductase	50 µCi / 1.85 MBq	1.753,75
ART-0771	Mitoxantrone, [³H(G)] M.W. 444.1	Ethanol 1 mCi/ml	1-5 Ci/mmol 37-185 GBq/mmol	Chemotherapeutic agent	anti-neoplastic	50 µCi / 1.85 MBq	1.173,00
ART-1467	POE-4, [³H] Polyoxyethylene-4 glycerol monolaurate	Ethanol 1 mCi/ml	12 mCi/mg 0.324 TBq/mg	Emulsifier, solubilizer and surfactant			Enquire
ART-1475	Pravastatin, [³H] M.W. 424.5	Ethanol	5-15 Ci/mmol 0.185-0.55 GBq/mmol	inhibitor	HMG-CoA reductase		Enquire
A3-AI-405	Sapoin C, [Tyr⁰ (¹²⁵I)] (13-27), human	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotrophic	uPAR	50 µCi / 1.85 MBq	1.483,50
ART-1166	TCPOBOP, [³H] C ₁₆ H ₈ Cl ₂ N ₂ O ₂ M.W. 402.1	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-1.11 TBq/mmol	tumor promoter	CYP450	50 µCi / 1.85 MBq	695,75
ART-0804	Trimipramine hydrochloride, [N-methyl-³H] M.W. 329.9	Ethanol 1 mCi/ml	70-87 Ci/mmol 2.59-3.22 TBq/mmol	inhibitor	NE and 5-HT uptake	50 µCi / 1.85 MBq	1.219,00
ART-1506	Tubercidin, [³H] 7-Deazaadenosine M.W. 266.3	Ethanol	10-30 Ci/mmol 0.37-1.11 TBq/mmol	antibiotic			Enquire
A3-AI-424	(D-Tyr⁵)-Triptorelin, [¹²⁵I] (D-Tyr ⁵ ,D-Trp ⁶)-LHRH	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	LHRH	50 µCi / 1.85 MBq	1.483,50

<i>Miscellaneous</i>							
<i>Cat.Nr.</i>	<i>Compound</i>	<i>Preparation</i>	<i>Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
ART-1309	Vinorelbine, [³H(G)] C ₂₅ H ₅₄ N ₂ O ₈ M.W. 778.93	Ethanol 1 mCi/ml	5-25 Ci/mmol 1.85-9.25 GBq/mmol	Chemotherapeutic agent	anti-neoplastic	50 µCi / 1.85 MBq	1.515,70
A3-AI-304	Vitronectin, (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	αVβ5 integrin	50 µCi / 1.85 MBq	1.753,75
A3-AI-294	VLDL, [¹²⁵I] Very Low Density Lipoprotein	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	lipoprotein	50 µCi / 1.85 MBq	1.753,75
<i>Neuropeptides</i>							
<i>Cat.No</i>	<i>Compound</i>	<i>Preparation</i>	<i>Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
BC107920	Neuropeptide Y1 Receptor, Human	lyophilized membrane	1.97 pmol/mg total protein	receptor	NPY1	200 U / 4 vials	655,50
BC108020	Neuropeptide Y2 Receptor, Human	lyophilized membrane	3.27 pmol/mg total protein	receptor	NPY2	200 U / 4 vials	655,50
BT-ES-450-M	Neuromedin U FM3 Receptor, Human	lyophilized membrane	36.4 and 54.5 pmol/mg total protein	receptor	FM3	200 U / vial	557,75
BT-ES-451-M	Neuromedin U FM4 Receptor, Human	lyophilized membrane	5.7 and 12.6 pmol/mg total protein	receptor	FM4	200 U / vial	557,75
BT-ES-490-M	Neuropeptide FF Receptor, Human	lyophilized membrane	0.736 and 1.104 pmol/mg total protein	receptor	NPFF2s	200 U / vial	557,75
BT-ES-690-M	Neurotensin Receptor, Human	lyophilized membrane	30.4 and 46.6 pmol/mg total protein	receptor	NTS ₁	200 U / vial	557,75
<i>Cat.No</i>	<i>Compound</i>	<i>Solvent</i>	<i>Spec. Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
A3-AI-360	AGRP, (fragment 1-132), [¹²⁵I] Agouti-Related Protein (1-132)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	MC3/MC4	50 µCi / 1.85 MBq	1.753,75
A3-AI-353	AGRP, (fragment 87-132), [¹²⁵I] Agouti-Related Protein (87-132)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	MC3/MC4	50 µCi / 1.85 MBq	1.753,75
A3-AI-491	β-Amyloid, (1-11), [3-(¹²⁵I)-Tyr], human	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotoxic		50 µCi / 1.85 MBq	1.483,50
A3-AI-551	β-Amyloid, (1-40), [3-(¹²⁵I)-Tyr], human	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotoxic		50 µCi / 1.85 MBq	1.483,50
A3-148	β-Amyloid, (1-42), [3-(¹²⁵I)-Tyr], human	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotoxic		50 µCi / 1.85 MBq	1.483,50
A3-AI-527	BDNF (human), [¹²⁵I] (Brain Derived Neurotrophic Factor)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotrophic		50 µCi / 1.85 MBq	1.753,75
ART-1455	BIIE0246, [³H] M.W. 896.06	Ethanol:water (1:1) 1 mCi/ml	20-50 Ci/mol 0.74-1.85 TBq/mmol	antagonist	NPY2		Enquire
A3-AI-289	GDNF (human), [¹²⁵I] (Glial Derived Neurotrophic Factor)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	neurotrophic	RET/ GDNFRα	50 µCi / 1.85 MBq	1.753,75
A3-AI-446	GR 231118, [(¹²⁵I)Tyr], 1229U91 / GW1229	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	NPY1	50 µCi / 1.85 MBq	1.753,75
A3-AI-458	Neuromedin U-25, (human), [(¹²⁵I)-Tyr]¹⁸	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	FM3/FM4	50 µCi / 1.85 MBq	1.483,50
A3-AI-409	Neuromedin U-25, (porcine), [(¹²⁵I)-Tyr]¹⁸	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	FM3/FM4	50 µCi / 1.85 MBq	1.483,50
A3-AI-410	Neuromedin U, (rat), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	FM3/FM4	50 µCi / 1.85 MBq	1.483,50
ART-1229	[Tyr⁴]-Neuropeptide FF (human), [Tyr-3,5-Pro-3,4-³H] M.W. 1384.0	Ethanol:water (1:1) 1 mCi/ml	100-120 Ci/mmol 3.7-4.44 TBq/mmol	analogue	NPFF2s	50 µCi / 1.85 MBq	563,50
A3-140	Neuropeptide Y, (human/rat) [¹²⁵I] Bolton-Hunter labeled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	NPY	50 µCi / 1.85 MBq	2.219,50

Neuropeptides							
Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-216	Neuropeptide Y , (3-36), (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	NPY2	50 µCi / 1.85 MBq	1.753,75
A3-AI-214	(D-Trp³²)-Neuropeptide Y , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	NPY	50 µCi / 1.85 MBq	1.753,75
A3-AI-116	(Leu³, Pro³⁴)-Neuropeptide Y , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	NPY1	50 µCi / 1.85 MBq	1.753,75
A3-AI-213	Neuropeptide Y , (porcine), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.753,75
A3-AI-171	Neurotensin , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	NT1	50 µCi / 1.85 MBq	1.483,50
A3-AI-403	NOGO-66 (1-40), [¹²⁵ I] NEP (1-40)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	NgR	50 µCi / 1.85 MBq	1.753,75
ART-1460	Oxytocin , [tyrosyl-2,6- ³ H] M.W. 1007.19	Ethanol: water (8:2) 1mCi/ml	20-40 Ci/mmol 0.74-1.48 TBq/mmol	stimulates uterine contraction	OT	250 µCi / 9.25 MBq	1.391,50
A3-AI-205	PACAP 27 amide, (human), [¹²⁵ I] (pituitary adenylate cyclase-activating polypeptide)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	PAC1	50 µCi / 1.85 MBq	1.483,50
A3-AI-425	Peptide YY , [3-(¹²⁵ I)-Tyr ³⁶] (PYY)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	NPY	50 µCi / 1.85 MBq	1.753,75
A3-AI-554	Peptide YY , (3-36), (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	NPY2	50 µCi / 1.85 MBq	1.753,75
A3-AI-553	(Leu³, Pro³⁴)-Peptide YY , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	NPY1	50 µCi / 1.85 MBq	1.753,75
A3-AI-567	(Pro³⁴)-Peptide YY , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	NPY	50 µCi / 1.85 MBq	1.753,75
A3-AI-505	(d(CH₂)₅¹, Tyr(Me)², Thr⁴, Orn⁸, Tyr-NH₂⁹)-Vasotocin , [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	OT	50 µCi / 1.85 MBq	1.483,50
Natriuretic Peptides							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-549	BNP-32 , (human), [3-(¹²⁵ I)-Tyr ⁰] Brain Natriuretic Peptide-32 (Nesiritide)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.483,50
ART-1275	Diuretic hormone analogue , [³ H] [para- ³ H-Phe ³⁷]Manse-DH[NIE ²¹¹] [Lys ³⁴] RNlePSLSIDLPNleSVLRQKLSLEKER KVHALRAAANKNFLNDI-NH ₂	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	insect hormon	CRF	50 µCi / 1.85 MBq	563,50
A3-103	ANF , (human), (99-126), [3-(¹²⁵ I)-Tyr ¹²⁶] Atrial Natriuretic Factor	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist		50 µCi / 1.85 MBq	1.483,50
A3-104	ANF , (rat), (99-126), [3-(¹²⁵ I)-Tyr ¹²⁶] Atrial Natriuretic Factor	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist		50 µCi / 1.85 MBq	1.483,50
A3-AI-470	Urocortin , (human), [(¹²⁵ I)-Tyr ⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	CRF	50 µCi / 1.85 MBq	1.483,50
A3-AI-278	Urocortin , (rat) [¹²⁵ I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	CRF	50 µCi / 1.85 MBq	2.219,50
A3-AI-466	Urocortin II , [3-(¹²⁵ I)-Tyr-Gly]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	CRF2	50 µCi / 1.85 MBq	1.483,50

Opioids and Sigma Ligands

Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-230-M	Nociceptin Receptor, Human	lyophilized membrane	0.624 and 4.21 pmol/mg total protein	receptor	ORL1	200 U / vial	557,75
BC108420	Opioid δ Receptor, Mouse	lyophilized membrane	2.20 pmol/mg total protein	receptor	δ receptor	200 U / 4 vials	655,50
BT-ES-541-M	Opioid κ Receptor, Human	lyophilized membrane	2.5 and 3.7 pmol/mg total protein	receptor	κ receptor	200 U / vial	557,75
BC108620	Opioid κ Receptor, Mouse	lyophilized membrane	2.54 pmol/mg total protein	receptor	κ receptor	200 U / 4 vials	655,50
BT-ES-542-M	Opioid μ Receptor, Human	lyophilized membrane	2.5 and 3.7 pmol/mg total protein	receptor	μ receptor	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0237	Dihydromorphine, [1,7,8-3H] M.W. 287.4	Ethanol under argon 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	agonist	μ receptor	250 μ Ci / 9.25 MBq	822,25
ART-0702	DAMGO, [tyrosyl-3,5-3H, (DAGO)] M.W. 513.7	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	agonist	μ receptor	250 μ Ci / 9.25 MBq	782,00
A3-AI-300	DAMGO, [125I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	μ receptor	50 μ Ci / 1.85 MBq	1.753,75
A3-AI-325	Dynorphin A (1-13), [125I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	κ receptor	50 μ Ci / 1.85 MBq	1.483,50
ART-0624	DTG, [5-3H], 1,3-Di-O-tolylguanidine Di-[p-ring-3H] M.W. 239.32	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	ligand	σ 1 and σ 2 receptor	250 μ Ci / 9.25 MBq	868,25
ART-1329	Fentanyl Citrate, [N-methyl-3H] $C_{22}H_{28}N_2O_6$, $C_6H_8O_7$ M.W. 528.6	Ethanol 1 mCi/ml	80-85 Ci/mmol 2.96-3.21 TBq/mmol	agonist	μ receptor	50 μ Ci / 1.85 MBq	954,50
ART-0603	Leu-Enkephalin, [Tyr1-3,5-3H] ([3,5- 3 H]Tyr-Gly-Gly-Phe-Leu-OH)	Ethanol under argon 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	endogenous agonist	δ receptor	250 μ Ci / 9.25 MBq	782,00
ART-1227	Endomorphin 1, [Tyr-3,5-3H] M.W. 611.0	Ethanol:water (1:1) 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	endogenous	μ receptor	50 μ Ci / 1.85 MBq	563,50
ART-1228	Endomorphin 2, [Tyr-3,5-3H] M.W. 572.0	Ethanol:water (1:1) 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	endogenous	μ receptor	50 μ Ci / 1.85 MBq	563,50
ART-0659	Morphine, [N-methyl-3H] M.W. 285.4	Ethanol under argon 1 mCi/ml	60-87 Ci/mmol 2.22-3.22 TBq/mmol	agonist	μ receptor	250 μ Ci / 9.25 MBq	868,25
ART-0139	Naloxone, [N-allyl 2,3-3H] M.W. 327.4	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	antagonist	μ receptor	250 μ Ci / 9.25 MBq	782,00
ART-1444	Naltriben, [3H] [3 H]-17-(Cyclopropylmethyl)-6,7-didehydro-3,14 β -dihydroxy-4,5 α -epoxy-6,7-2',3'-benzo[b]furanomorphinan M.W. 415.48	Ethanol:water (1:1) 1 mCi/ml	20-30 Ci/mmol 0.74-1.11 TBq/mmol	antagonist	δ receptor	250 μ Ci / 9.25 MBq	1.075,25
ART-0549	Naltrindole, [3H] [5',7'- 3 H]-17-(Cyclopropylmethyl)-6,7-dehydo-4,5 α -epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan M.W. 414.50	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	antagonist	δ receptor	250 μ Ci / 9.25 MBq	695,75
ART-0726	Nociceptin, [Leucyl 3,4,5-3H] Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu (3,4,5- 3 H)-Ala-Asn-Gln M.W. 1808.1	0.1 N AcOH:EtOH (8:2) 1 mCi/ml	80-100 Ci/mmol 2.96-3.7 TBq/mmol	agonist	ORL1	50 μ Ci / 1.85 MBq	2.236,75

Opioids and Sigma Ligands

Cat.Nr.	Compound	Solvent	Spec. Activity	Pharmacol. Action	Selectivity	Size	Price €
ART-0736	Nociceptin, [p-³H-Phe¹] Phe(3H)-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gly M.W. 1808.1	0.1 N AcOH:EtOH (8:2) 1 mCi/ml	25-50 Ci/mmol 0.925-1.85 TBq/mmol	agonist	ORL1	50 µCi / 1.85 MBq	1.610,00
ART-0725	Nociceptin (Tyr²⁴) [tyrosyl 3,5-³H] Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Tyr (3,5- ³ H)-Ala-Asn-Gln M.W. 1859.1	0.1 N AcOH:EtOH (8:2) 1 mCi/ml	25-50 Ci/mmol 0.925-1.85 TBq/mmol	agonist	ORL1	50 µCi / 1.85 MBq	2.236,75
ART-0756	Nocistatin, [Pro-3,4-³H] (Bovine) (³ H PNP-3) Thr-Glu-Pro[3,4- ³ H]-Gly-Leu-Glu-Glu-Val-Gly-Glu-Ile-Glu-Gln-Lys-Gln-Leu-Gln) (Pre-pro-orphanin F2 111-127) M.W. 1927.1	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous antagonist		50 µCi / 1.85 MBq	724,50
ART-0878	SNC 121, [³H] (4-[(aR)-a-((2S,5R)-4([2',3'- ³ H])-propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) M.W. 451.64	Ethanol:water (1:1) 1 mCi/ml	20-50 Ci/mol 0.74-1.85 TBq/mmol	agonist	δ receptor	250 µCi / 9.25 MBq	1.299,50

Orexins

Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-330-M	Orexin OX1 receptor, Human	lyophilized membrane	8.2 and 12.4 pmol/mg total protein	receptor	OX1	200 U / vial	557,75
BT-ES-331-M	Orexin OX2 receptor, Human	lyophilized membrane	Enquire	receptor	OX2	200 U / vial	557,75
BT-ES-670-M	Orexin OX2 like receptor, Human	lyophilized membrane	Enquire	receptor	OX2 like	200 U / vial	557,75

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-164	Orexin A, (human,mouse, rat), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous agonist	OX1/2	50 µCi / 1.85 MBq	1.483,50
ART-0754	Orexin B, (human), [proline^{4,5}-3,4-³H] M.W. 2899.1	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous agonist	OX2	50 µCi / 1.85 MBq	724,50
A3-AI-164	Orexin B, (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous agonist	OX2	50 µCi / 1.85 MBq	1.483,50
A3-AI-330	Orexin B, (rat/mouse), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous agonist	OX2	50 µCi / 1.85 MBq	1.483,50
ART-0764	Orexin-B, (rat,mouse), [proline²-3,4-³H] M.W. 2936.5	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	endogenous agonist	OX2	50 µCi / 1.85 MBq	563,50

<i>Peptides / Miscellaneous</i>							
<i>Cat.No</i>	<i>Compound</i>	<i>Preparation</i>	<i>Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
BT-ES-610-M	Chemotactic Formyl peptide Receptor, Human	lyophilized membrane	84 and 126 pmol/mg total protein	receptor	FPRL-1	200 U / vial	557,75
BT-ES-730-M	Chemotactic peptide C3a Receptor, Human	lyophilized membrane	17.5 and 26.3 pmol/mg total protein	receptor	C3a	200 U / vial	557,75
BT-ES-730-CF	Chemotactic peptide C3a cells, Human	frozen cells	functional GPCR testing	cAMP	C3a	100 units	517,50
BT-ES-731-M	Chemotactic peptide C5a Receptor, Human	lyophilized membrane	Enquire	receptor	C5a	200 U / vial	557,75
BT-ES-731-CF	Chemotactic peptide C5a cells , Human	frozen cells	functional GPCR testing	cAMP	C5a	100 units	517,50
BT-ES-630-M	Metastatine Receptor, Human	lyophilized membrane	0.33 and 0.49 pmol/mg total protein	receptor	GPR54	200 U / vial	557,75
BT-ES-380-M	Motilin Receptor, Human	lyophilized membrane	19.2 and 28.8 pmol/mg total protein	receptor	GPR38	200 U / vial	557,75
BT-ES-330-M	Prolactin Related Peptide Receptor, Human	lyophilized membrane	36 and 54 pmol/mg total protein	receptor	GPR10	200 U / vial	557,75
BT-ES-440-M	Urotensin II Receptor, Human	lyophilized membrane	2.14 and 4.7 pmol/mg total protein	receptor	GPR14	200 U / vial	557,75
<i>Cat.No</i>	<i>Compound</i>	<i>Solvent</i>	<i>Spec. Activity</i>	<i>Pharma. Action</i>	<i>Selectivity</i>	<i>Size</i>	<i>Price €</i>
A3-AI-417	Antarelix, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	GnRH	50 µCi / 1.85 MBq	1.483,50
A3-AI-423	Cetrorelix, [¹²⁵I] (D-20761 Dekapeptide)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	GnRH	50 µCi / 1.85 MBq	1.483,50
A3-AI-408	ACTH (1-39), [3-(¹²⁵I)-Tyr] (Corticotropin)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.483,50
A3-147	Amylin, (human), [3-(¹²⁵I)-Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	diabetes	associated	50 µCi / 1.85 MBq	1.483,50
A3-AI-148	Amylin, (rat), [¹²⁵I] Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	diabetes	associated	50 µCi / 1.85 MBq	2.219,50
L9020	C-Peptide, (human), [¹²⁵I]	lyophilized	658 µCi/µg 24.35MBq/µg	diabetes	associated	3 µCi / 111 kBq	155,25
L9023	C-Peptide, (porcine), [¹²⁵I]	lyophilized	717µCi/µg 26.53MBq/µg	diabetes	associated	3 µCi / 111 kBq	155,25
L9022	C-Peptide, (rat), [¹²⁵I]	lyophilized	630 µCi/µg 23.31MBq/µg	diabetes	associated	3 µCi / 111 kBq	155,25
A3-AI-336	β-Defensin-2, BD-2, (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	cationic peptide	anti- microbial	50 µCi / 1.85 MBq	1.483,50
A3-AI-252	GIP, (human), [¹²⁵I] Glucose-dependent Insulinotropic Polypeptide	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	diabetes	associated	50 µCi / 1.85 MBq	1.483,50
A3-AI-474	GIP (1-42), (human), [¹²⁵I] Glucose-dependent Insulinotropic Polypeptid	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	diabetes	associated	50 µCi / 1.85 MBq	1.483,50
A3-AI-336X	Glucagon, (1-29), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmo	analogue	diabetes	50 µCi / 1.85 MBq	1.483,50
A3-AI-422	GLP-1 (7-36), [¹²⁵I] Glucagon-like Peptide 1 amide (7-36) (human)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GIP-1	50 µCi / 1.85 MBq	1.483,50
A3-AI-233	GLP-1, [¹²⁵I] Glucagon-like Peptide 1 amide (human)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	diabetes	50 µCi / 1.85 MBq	1.483,50

<i>Peptides / Miscellaneous</i>							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-400	Insulin , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	diabetes	50 µCi / 1.85 MBq	1.753,75
A3-AI-220	Insulin , (rat), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmo	endogenous	diabetes	50 µCi / 1.85 MBq	1.753,75
A3-162	Leptin , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	OB-R	50 µCi / 1.85 MBq	1.753,75
A3-163	Leptin , (mouse), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	OB-R	50 µCi / 1.85 MBq	1.753,75
A3-AI-277	Leptin , (rat), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	OB-R	50 µCi / 1.85 MBq	1.753,75
A3-AI-221	Pancreatic Polypeptide , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 µCi / 1.85 MBq	1.753,75
L9015	Proinsulin , (human), [¹²⁵ I]	lyophilized	367 µCi/µg 13.58/µg	diabetes	associated	3 µCi / 111 kBq	155,25
A3-AI-257	Prolactin , (mouse), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmo	endogenous		50 µCi / 1.85 MBq	1.753,75
ART-1225	PrRP-20 (human), [Pro ^{2,6,16} - 3,4 - ³ H] Prolactin-releasing Peptide-20 M.W. 2272.0	Ethanol:water (1:1) 1 mCi/ml	150-180 Ci/mmol 5.55-6.66 TBq/mmol	endogenous	GPR10	50 µCi / 1.85 MBq	563,50
A3-AI-322	PrRP-31 , [¹²⁵ I] Prolactin-releasing Peptide-31 Bolton-Hunter labelled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GPR10	50 µCi / 1.85 MBq	2.219,50
ART-1231	Rosiglitazone , [³ H] C ₁₈ H ₁₉ N ₃ O ₅ M.W. 357,4	Ethanol 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	potent insulin sensitizer	PPARγ	250 µCi / 9.25 MBq	1.132,75
A3-AI-395	Urotensin II , (human), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GPR14	50 µCi / 1.85 MBq	1.483,50
A3-AI-402	Urotensin II , (rat), [¹²⁵ I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	GPR14	50 µCi / 1.85 MBq	1.483,50
A3-AI-494	Urotensin-Related-Peptide , [3-(¹²⁵ I)Tyr] URP	lyophilized 81.4 TBq/mmol	2.200 Ci/mmol	endogenous	GPR14	50 µCi / 1.85 MBq	1.483,50
A3-131	Vasoactive Intestinal Contractor [3-(¹²⁵ I)Tyr], VIC	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	endothelin-like	50 µCi / 1.85 MBq	1.483,50
A3-AI-454	W-Peptide , [¹²⁵ I] WKYMVm	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	FPRL1	50 µCi / 1.85 MBq	1.483,50
ART-0868	WY-14643 , [³ H(G)] (4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid) C ₁₄ H ₁₄ ClN ₃ O ₂ S M.W. 323.8	Ethanol 1 mCi/ml	5-15 Ci/mmol 0.185-0.555 TBq/mmol	agonist	PPARα	250 µCi / 9.25 MBq	1.219,00

<i>Prostanoids</i>							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-561-M	Prostanoid CRTH2 Receptor, Human	lyophilized membrane	10.24 and 15.36 pmol/mg total protein	receptor	CRTH2	200 U / vial	557,75
BT-ES-560-M	Prostanoid DP Receptor, Human	lyophilized membrane	1.22 and 1.84 pmol/mg total protein	receptor	DP	200 U / vial	557,75
BT-ES-562-M	Prostanoid EP2 Receptor, Human	lyophilized membrane	2.7 and 4.8 pmol/mg total protein	receptor	EP ₂	200 U / vial	557,75
BT-ES-563-M	Prostanoid EP4 Receptor, Human	lyophilized membrane	1.6 and 2.4 pmol/mg	receptor	EP ₄	200 U / vial	557,75
BT-ES-564-M	Prostanoid FP Receptor, Human	lyophilized membrane	Enquire	receptor	FP	200 U / vial	557,75

Prostanoids							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0662	Prostaglandin D₂, [5,6,8,9,12,14,15-3H] (PGD₂) M.W. 352.47	70% Ethanol under nitrogen in silanized vial 1 mCi/ml	100-210 Ci/mmol 3.7-7.8 TBq/mmol		DP	25 µCi / 0.93 MBq	793,50
ART-0664	Prostaglandin E₂, [5,6,8,11,12,14,15-3H] (PGE₂) M.W. 352.47	70% Ethanol under nitrogen in silanized vial 1 mCi/ml	100-210 Ci/mmol 3.7-7.8 TBq/mmol		EP	25 µCi / 0.93 MBq	997,00
ART-0604	Prostaglandin F_{2α}, [5,6,8,9,12,14,15-3H] (PGF_{2α}) M.W. 354.49	70% Ethanol under nitrogen in silanized vial 1 mCi/ml	150-240 Ci/mmol 5.55-8.88 TBq/mmol		FP	25 µCi / 0.93 MBq	1.006,25

Retinoids							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0556	Retinol, [15-³H(N)] "Vitamin A alcohol" M.W. 286.4	Ethanol under argon 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	RPB	250 µCi / 9.25 MBq	368,00

Serotonergics							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-310-M	Serotonin 5HT1A Receptor, Human	lyophilized membrane	0.45 and 4.6 pmol/mg total protein	receptor	5HT _{1A}	200 U / vial	557,75
BC100220	Serotonin 5HT1B Receptor, Human	lyophilized membrane	17.7 pmol/mg total protein	receptor	5HT _{1B}	200 U / 4 vials	655,50
BC100320	Serotonin 5HT1D Receptor, Human	lyophilized membrane	1.53 pmol/mg total protein	receptor	5HT _{1D}	200 U / 4 vials	655,50
BC100420	Serotonin 5HT1E Receptor, Human	lyophilized membrane	6.53 pmol/mg total protein	receptor	5HT _{1E}	200 U / 4 vials	655,50
BC100420	Serotonin 5HT1F Receptor, Human	lyophilized membrane	0.77 pmol/mg total protein	receptor	5HT _{1F}	200 U / 4 vials	655,50
BT-ES-313-M	Serotonin 5HT2A Receptor, Human	lyophilized membrane	0.29 and 6.8 pmol/mg total protein	receptor	5HT _{2A}	200 U / vial	557,75
BT-ES-313-M	Serotonin 5HT2B Receptor, Human	lyophilized membrane	0.87 and 5.3 pmol/mg total protein	receptor	5HT _{2B}	200 U / vial	557,75
BT-ES-315-M	Serotonin 5HT2C Receptor, Human	lyophilized membrane	5 and 31.6 pmol/mg total protein	receptor	5HT _{2C}	200 U / vial	557,75
BT-ES-401-M	Serotonin 5HT5a Receptor, Human	lyophilized membrane	2.7 and 4.1 pmol/mg total protein	receptor	5HT _{5a}	200 U / vial	557,75
BT-ES-316-M	Serotonin 5HT6 Receptor, Human	lyophilized membrane	6.8 and 10.2 pmol/mg total protein	receptor	5HT ₆	200 U / vial	557,75
BC111120	Serotonin 5HT6 Receptor, Rat	lyophilized membrane	3.58 pmol/mg total protein	receptor	5HT ₆	200 U / 4 vials	655,50
BC111720	Serotonin 5HT7 Receptor, Rat	lyophilized membrane	32.1 pmol/mg total protein	receptor	5HT ₇	200 U / 4 vials	655,50

Serotonergics							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-1402	Azidoimipramine, [methyl-³H] C ₁₉ H ₂₄ N ₄ . HCl M.W. 344.87	Ethanol 1 mCi/ml	70-85 Ci/mmol 2.96-3.14 TBq/mmol	reuptake inhibitor, photo affinity labeling reagent	5HT	50 µCi / 1.85 MBq	914,25
ART-1331	Fluoxetine hydrochloride, [N-methyl ³H] C ₁₇ H ₁₈ F ₃ . HCl M.W. 345.8	Ethanol 1 mCi/ml	80-85 Ci/mmol 2.96-3.21 TBq/mmol	reuptake inhibitor	5HT	50 µCi / 1.85 MBq	954,50
ART-0379	Imipramine hydrochloride, [N-methyl-³H] M.W. 316.9	Ethanol under nitrogen 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	reuptake inhibitor	5HT	250 µCi / 9.25 MBq	741,75
ART-0750	8-Hydroxy-DPAT, [propyl-2,3-ring-1,2,3-³H] M.W. 247.4	Ethanol under argon 1 mCi/ml	120-200 Ci/mmol 4.81-7.40 TBq/mmol	agonist	5HT _{1A}	250 µCi / 9.25 MBq	563,50
ART-1487	RS102221 hydrochloride, [³H] C ₂₇ H ₃₁ F ₃ N ₃ O ₃ . HCl M.W. 649.08	Ethanol:water (1:1) 1 mCi/ml	10-25 Ci/mmol 370-925 GBq/mmol	antagonist	5HT _{2C}		Enquire
A3-AI-074	8-MeO-N-PAT, [¹²⁵I] (Bolton-Hunter labelled)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	5HT _{1A}	50 µCi / 1.85 MBq	2.219,50

Signal Transduction Agents							
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0163	Adenosine-3',5'-cyclic phosphate, [2,8-³H], ammonium salt (cyclic AMP) M.W. 346.3	Ethanol:water (1:1) 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	2nd messenger		250 µCi / 9.25 MBq	253,00
A3-AI-198	alpha-Amanitin, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol"	toxin	RNA poly- merase II inhibitor	50 µCi / 1.85 MBq	1.753,75
ART-1421	Arginine, L-[2,3,4,5-³H] H ₂ NC(NH)NH(CH ₂) ₂ CH ₂ CH(NH ₂) COOH.HCl M.W. 174.2	2% Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	NO	250 µCi / 9.25 MBq	166,75
A3-AI-539	Cardiolipin, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	Complement activator	50 µCi / 1.85 MBq	1.753,75
ART-0146	Cytidine, [5-³H] M.W. 243.2	Sterile water 1 mCi/ml	20-30 Ci/mmol 0.74-1.11 TBq/mmol	DAG		250 µCi / 9.25 MBq	207,00
ART-1491	Dihydrosphingosine, [3-³H] M.W. 301.48	Ethanol 0.1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	inhibitor	protein kinase C	10 µCi / 370 kBq	609,50
ART-0125	Folic acid, sodium salt, [3,5,7,9-³H] C ₁₉ H ₁₉ N ₇ O ₆ M.W. 441.4	Ethanol:water (1:1) 1 mCi/ml	20-70 Ci/mmol 0.74-2.59 TBq/mmol	coenzyme		250 µCi / 9.25 MBq	695,75
ART-0372	Guanosine 3',5'-cyclic phosphate, [guanosine 8-³H] (cyclic GMP) M.W. 362.3	Ethanol:water (1:1) 1 mCi/ml	10-30 Ci/mmol 0.37-1.11 TBq/mmol	2nd messenger		250 µCi / 9.25 MBq	368,00
A3-135	Guanylin, [3-(¹²⁵I)-Tyr⁹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	activator	intestinal guanylate cyclase	50 µCi / 1.85 MBq	1.483,50
ART-0872	Inositol 1,3,4,5-tetrakisphosphate, D-[inositol-2-³H(N)] M.W. 493.96	50mM Ammonium Phosphate buffer (pH 8.0) under nitrogen 0.1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	analogue	Ca ²⁺ channel opener	5 µCi / 185 kBq	839,50
ART-0270	Inositol-1,4,5-trisphosphate, D-[inositol-1-³H(N)] M.W. 416.98	Sterile water 0.1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	mobilises Ca ²⁺	5 µCi / 185 kBq	736,00
ART-1502	Lipoxin A4, [11,12-³H] M.W. 352.47	Ethanol 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	activator	protein kinase C		Enquire

Signal Transduction Agents

Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-302	Mastoparan, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	activator	Gi/Go	50 µCi / 1.85 MBq	1.483,50
A3-AI-123	Methotrexate, [¹²⁵I] (+)Amethopterin	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	antagonist	folic acid	50 µCi / 1.85 MBq	1.753,75
ART-1117	Ochratoxin A, [³H(G)] C ₂₃ H ₁₉ ClNO ₆ M.W. 403.82	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 TBq/mmol	Mycotoxin	Ca ²⁺	250 µCi / 9.25 MBq	782,00
ART-0898	Ochratoxin B, [³H(G)] C ₂₀ H ₁₉ NO ₆ M.W. 369.4	Ethanol 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 TBq/mmol	Mycotoxin	Ca ²⁺	250 µCi / 9.25 MBq	822,25
ART-0487	Phorbol 12,13-diacetate, [20-³H(N)], [³H-PDA] M.W. 448.5	Acetone under argon 1 mCi/ml	10-20 Ci/mmol 0.37-0.74 GBq/mmol	activator	PKC	50 µCi / 1.85 MBq	287,50
ART-0485	Phorbol 12,13-dibutyrate, [20-³H(N)], [³H-PDBu] M.W. 504.6	Acetone under argon 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	activator	PKC	50 µCi / 1.85 MBq	299,00
ART-0486	Phorbol-12-myristate-13-acetate, [20-³H(N)] [³H-PMA] M.W. 616.8	Acetone under argon 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	activator	PKC	50 µCi / 1.85 MBq	304,75
ART-0184	Phosphatidylinositol, L-α-[myo-inositol-2-³H(N)] PI [³H] M.W. 886	CHCl ₃ :MeOH (1:1) in sealed ampoule 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	PLC substrate	50 µCi / 1.85 MBq	1.679,00
ART-0183	Phosphatidylinositol 4,5-bisphosphate, [myo-inositol-2-³H(N)] PIP₂ [³H] M.W. 1046	CHCl ₃ :EtOH:H ₂ O (20:10:1) 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	PLC/PI3K substrate	5 µCi / 185 kBq	724,50
ART-0185	Phosphatidylinositol 4-phosphate, [myo-inositol-2-³H] M.W. 966.2	CHCl ₃ :MeOH (1:1) 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	PIPK/PI3K substrate	5 µCi / 185 kBq	839,50
ART-0727	Platelet activating factor, [acetyl-³H] (1-O hexadecyl-2-O-acetyl-sn-glycero-3-PC CAF C16) C ₂₆ H ₅₄ NO ₇ P M.W. 523.7	Ethanol 1 mCi/ml	5-20 Ci/mmol 0.185-0.74 TBq/mmol	endogenous	PAF receptor	250 µCi / 9.25 MBq	1.299,50
ART-0481	Sphingomyelin, (bovine), [choline-methyl-³H]	Toluene:methanol (1:1) in silanized ampoule 1 mCi/ml	60-90 Ci/mmol 2.22-3.33 TBq/mmol	endogenous		50 µCi / 1.85 MBq	661,25
ART-0490	Sphingosine, D-erythro-[3-³H] D(+) erythro-2-amino-4-transoctadecene-1,3-diol M.W. 299.5	Ethanol under nitrogen 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	endogenous	PKC inhibitor	50 µCi / 1.85 MBq	609,50
ART-0859	Sphingosine, D-threo [3-³H] M.W. 299.5	Ethanol under nitrogen 1 mCi/ml	15-30 Ci/mmol 0.55-1.11 TBq/mmol	stereo isomer	ceramide	50 µCi / 1.85 MBq	782,00

Somatostatins / SRIF							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-520-M	Somatostatin SST1 Receptor, Human	lyophilized membrane	8.2 and 12.4 pmol/mg total protein	receptor	sst ₁	200 U / vial	557,75
BC109420	Somatostatin SST2 Receptor, Human	lyophilized membrane	0.25 pmol/mg total protein	receptor	sst ₂	200 U / 4 vials	655,50
BT-ES-521-M	Somatostatin SST2A Receptor, Human	lyophilized membrane	15 and 22.4 pmol/mg total protein	receptor	sst _{2A}	200 U / vial	557,75
BT-ES-523-M	Somatostatin SST3 Receptor, Human	lyophilized membrane	10.2 and 15.3 pmol/mg total protein	receptor	sst ₃	200 U / vial	557,75
BT-ES-524-M	Somatostatin SST4 Receptor, Human	lyophilized membrane	11.9 and 17.9 pmol/mg total protein	receptor	sst ₄	200 U / vial	557,75
BT-ES-522-M	Somatostatin SST5 Receptor, Human	lyophilized membrane	12.6 and 19 pmol/mg total protein	receptor	sst ₅	200 U / vial	557,75
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-465	Lanreotide, [3-(¹²⁵I)Tyr]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Somatostatin analogue	SRIF	50 µCi / 1.85 MBq	1.483,50
A3-AI-042	Sandostatin, (SMS 201-995) [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	Somatostatin analogue	SRIF	50 µCi / 1.85 MBq	1.753,75
A3-132	Somatostatin, (1-14), [3-(¹²⁵I)Tyr¹¹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	SRIF	50 µCi / 1.85 MBq	1.483,50
A3-AI-141 [3-(¹²⁵ I)Tyr ⁹]	Somatostatin, (1-28), [3-(¹²⁵I)Tyr⁹]	lyophilized 81.4 TBq/mmol	2.200 Ci/mmol	agonist	SRIF	50 µCi / 1.85 MBq	1.483,50
A3-159	Somatostatin, (1-28), [3-(¹²⁵I)Tyr¹¹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	SRIF	50 µCi / 1.85 MBq	1.483,50
A3-AI-143	(Leu⁸, D-Trp²², Tyr²⁵) Somatostatin 28, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	SRIF	50 µCi / 1.85 MBq	1.483,50
Steroids							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-700-M	TRH, Thyrotropin Releasing Hormone, Receptor, Human	lyophilized membrane	11.8 and 17.8 pmol/mg total protein	receptor	TRHR1	200 U / vial	557,75
BT-ES-700-AF	TRH cells	frozen cells	functional GPCR testing	aequorin	TRHR1	100 units	517,50
Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0648	Androst-4-ene-3,17-dione, [1β,2β-³H] M.W. 286.4	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	androgen	250 µCi / 9.25 MBq	345,00
ART-0649	Androst-4-ene-3,17-dione, [1,2,6,7-³H] C₁₉H₂₆O₂ M.W. 286.4	Ethanol 1 mCi/ml	80-120 Ci/mmol 2.96-4.44 TBq/mmol	endogenous	androgen	250 µCi / 9.25 MBq	506,00
ART-1253	Androst-5-ene-17-one, [1,2-³H] C₁₉H₂₇O M.W. 272.42	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	androgen	50 µCi / 1.85 MBq	563,50
ART-1172	Androsterone, [9,11-³H(N)] C₁₉H₃₀O₂ M.W. 290.4	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	androgen	50 µCi / 1.85 MBq	754,00
ART-0743	Cortisone, [1,2-³H] M.W. 360.45	Ethanol 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	synthetic	corticoid	250 µCi / 9.25 MBq	609,50

Steroids							
Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-1273	11-Deoxycortisol, [1,2-³H] 17 α , 21-Dihydroxypregn-4-ene-3,20-dione M.W. 346.47	Ethanol 1 mCi/ml	30-60 Ci/mmol 1.11-2.22 TBq/mmol	analogue	corticoid	250 μ Ci / 9.25 MBq	1.132,75
ART-1352	21-Deoxycortisol, [1,2-³H] C ₂₁ H ₃₀ O ₄ M.W. 346.47	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	analogue	corticoid	50 μ Ci / 1.85 MBq	914,25
ART-0769	Dihydrotestosterone, [1,2-³H] M.W. 290.41	Ethanol 1 mCi/ml	40-60 mCi/mmol 1.48-2.22 GBq/mmol	endogenous	androgen	250 μ Ci / 9.25 MBq	782,00
ART-0796	Dihydrotestosterone, [1,2,4,5,6,7-³H] M.W. 290.41	Ethanol 1 mCi/ml	110-150 Ci/mmol 4.07-5.55 TBq/mmol	endogenous	androgen	250 μ Ci / 9.25 MBq	885,80
ART-0820	Estradiol, [6,7-³H(N)] M.W. 272.4	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	estrogen	250 μ Ci / 9.25 MBq	310,50
ART-1321	Ethynylestradiol, 17α-[6,7-³H(N)] M.W. 296.4	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	synthetic	estrogen	250 μ Ci / 9.25 MBq	1.006,25
A3-AI-541	Follicle Stimulating Hormone, (human), FSH, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 μ Ci / 1.85 MBq	1.753,75
ART-0776	Hydrocortisone, [1,2-³H] (cortisol) M.W. 362.47"	Ethanol 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol"	analogue	corticoid	250 μ Ci / 9.25 MBq	345,00
ART-0638	Hydroxyprogesterone, 17α-[1,2,6,7-³H] M.W. 330.5	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	pro-gesteron	250 μ Ci / 9.25 MBq	345,00
ART-0891	20α-Hydroxyprogesterone, [1,2-³H(N)] M.W. 316.47	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 TBq/mmol	endogenous	pro-gesteron	250 μ Ci / 9.25 MBq	609,50
ART-1288	2-Methoxyestradiol, [6,7-³H] M.W. 302.4	Solid	30-60 Ci/mmol 1.11-2.22 TBq/mmol	analogue		50 μ Ci / 1.85 MBq	506,00
A3-AI-500	Oxytocin, [(¹²⁵I)Tyr⁹]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	OT	50 μ Ci / 1.85 MBq	1.483,50
ART-0542	Ponasterone A, [24,25,26, 27-³H(N)] C ₂₇ H ₄₄ O ₆ M.W. 464.65	Ethanol 1 mCi/ml	120-200 Ci/mmol 4.44-7.4 TBq/mmol	Ecdysone analogue		50 μ Ci / 1.85 MBq	782,00
A3-AI-120	pTH, (human), (1-34), [(¹²⁵I)Tyr⁰] (parathyroid hormone)	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	analogue	PTH	50 μ Ci / 1.85 MBq	1.483,50
ART-1446	PPT, [³H] 1-(3-[³ H]-4-Hydroxyphenyl)-3,5-(3-[³ H]-4-hydroxyphenyl)-4-propyl-1H-pyrazole M.W. 386.45	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	agonist	E α	250 μ Ci / 9.25 MBq	1.311,00
ART-1134	Progesterone, [1,2,6,7,16,17-³H] M.W. 314.5	Toluene 1 mCi/ml	100-130 Ci/mmol 3.7-4.8 TBq/mmol	endogenous	pro-gesteron	250 μ Ci / 9.25 MBq	437,00
ART-0897	RU-486 [N-methyl-³H], (Mifepristone) M.W. 429.6	Ethanol 1 mCi/ml	60-85 Ci/mmol 2.22-3.15 TBq/mmol	antagonist	pro-gesteron	50 μ Ci / 1.85 MBq	649,75
A3-AI-499	Secretin, [¹²⁵I-Tyr¹⁰]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 μ Ci / 1.85 MBq	1.483,50
ART-0684	Tamoxifen methiodide, [N-methyl-³H] M.W. 513.4	Ethanol 1 mCi/ml	80-90 Ci/mmol 2.96-3.33 TBq/mmol	partial agonist	estrogen	250 μ Ci / 9.25 MBq	649,75
ART-0780	Testosterone, [1α, 2α-³H] M.W. 288.41	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 GBq/mmol	endogenous	androgen	250 μ Ci / 9.25 MBq	345,00

Steroids							
Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-1215	Testosterone [1β, 2β-³H(N)] C ₁₉ H ₂₈ O ₂ M.W. 288.41	Ethanol 1 mCi/ml	40-60 Ci/mmol 1.48-2.22 GBq/mmol	endogenous	androgen	250 μ Ci / 9.25 MBq	478,80
ART-0768	Testosterone, [1,2,6,7-³H] M.W. 288.41	Ethanol 1 mCi/ml	85-105 Ci/mmol 3.15-3.89 TBq/mmol	endogenous	androgen	250 μ Ci / 9.25 MBq	538,80
A3-AI-251	Thyroid Stimulating Hormone, (TSH) (human), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 μ Ci / 1.85 MBq	1.525,00
A3-AI-117	Thyroid Stimulating Hormone, (TSH) (rat), [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous		50 μ Ci / 1.85 MBq	1.525,00
ART-0705	Thyrotropin Releasing Hormone, [pro 3,4-³H] M.W. 376.4	Ethanol 1 mCi/ml	50-60 Ci/mmol 1.85-2.22 TBq/mmol	endogenous	TRHR1	50 μ Ci / 1.85 MBq	715,00

Tachykinins							
Cat.No	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-251-M	Neurokinin NK1 Receptor, Human	lyophilized membrane	18 and 32.18 pmol/mg total protein	receptor	NK ₁	200 U / vial	557,75
BC107320	Neurokinin NK1 Receptor, Rat	lyophilized membrane	68.9 pmol/mg total protein	receptor	NK ₁	200 U / 4 vials	655,50
BC107420	Neurokinin NK2 Receptor, Human	lyophilized membrane	3.55 pmol/mg total protein	receptor	NK ₂	200 U / 4 vials	655,50
BC107520	Neurokinin NK2 Receptor, Rat	lyophilized membrane	41.6 pmol/mg total protein	receptor	NK ₂	200 U / 4 vials	655,50
BT-ES-252-M	Neurokinin NK3 Receptor, Human	lyophilized membrane	2.35 and 3.53 pmol/mg total protein	receptor	NK ₃	200 U / vial	557,75

Cat.No	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
ART-0692	Substance P, [leucyl 3,4,5-³H]	Ethanol 1 mCi/ml	>100 Ci/mmol	agonist	NK ₁	250 μ Ci / 9.25 MBq	2.001,00
ART-0693	Substance P, [2-L-pro-3,4-³H] M.W. 1347.80	Ethanol 1 mCi/ml	25-50 Ci/mmol 0.925-1.85 TBq/mmol	agonist	NK ₁	250 μ Ci / 9.25 MBq	2.087,25
A3-160	Substance P, [¹²⁵I] Bolton-Hunter labeled	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	NK ₁	50 μ Ci / 1.85 MBq	2.219,50
A3-165	Neurokinin A, [His³(¹²⁵I)]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	NK ₂	50 μ Ci / 1.85 MBq	1.753,75
A3-166	(N-Me-Phe⁷) Neurokinin B, [His³(¹²⁵I)]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	NK ₃	50 μ Ci / 1.85 MBq	1.753,75
ART-1213	SB 222200, [³H] [5- ³ H]-3-Methyl-2-[4- ³ H]phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide M.W. 380.48	Ethanol:water (1:1) 1 mCi/ml	30-50 Ci/mmol 1.11-1.85 TBq/mmol	antagonist	NK ₃	250 μ Ci / 9.25 MBq	1.040,75

Vasopressins							
Cat.Nr.	Compound	Preparation	Activity	Pharma. Action	Selectivity	Size	Price €
BT-ES-361-M	Vasopressin V1a Receptor, Human	lyophilized membrane	3.8 and 5.7 pmol/mg total protein	receptor	V1a	200 U / vial	557,75
BT-ES-362-M	Vasopressin V1b Receptor, Human	lyophilized membrane	7.5 and 11.3 pmol/mg total protein	receptor	V1b	200 U / vial	557,75
BT-ES-360-M	Vasopressin V1b Receptor, rat	lyophilized membrane	19.15 and 29.5 pmol/mg total protein	receptor	V1b	200 U / vial	557,75
BT-ES-363-M	Vasopressin V2 Receptor, Human	lyophilized membrane	17.9 and 26.9 pmol/mg total protein	receptor	V2	200 U / vial	557,75
BT-ES-363-AF	Vasopressin V2 cells, Human	frozen cells	functional GPCR testing	cAMP	V2	100 units	517,50

Vasopressins							
Cat.Nr.	Compound	Solvent	Spec. Activity	Pharma. Action	Selectivity	Size	Price €
A3-AI-218	Desmopressin, [¹²⁵I]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	agonist	V2	50 µCi / 1.85 MBq	1.483,50
ART-1232	Vasopressin, [Pro, 3,4-³H, Tyr 3,5-³H] [Phenyl-Acetyl-D-Tyr(me)Phe- Gln-Asn-Arg-(3,4³H-Pro)- (3,5-³H-Tyr)-NH₂ M.W. 1119.18	Ethanol:water 1 mCi/ml	80-120 Ci/mmol 2.96-4.44 TBq/mmol	analogue	V	Enquire	Enquire
ART-0703	Vasopressin, [Arg⁸, tyrosyl-3,5-³H] M.W. 1085.2	Ethanol:0.05N HOAc (7:3) 1 mCi/ml	60-85 Ci/mmol 2.22-3.15 TBq/mmol	endogenous	V	250 µCi / 9.25 MBq	1.000,50
A3-AI-413	Vasopressin, [Arg⁸(¹²⁵I)]	lyophilized	2.200 Ci/mmol 81.4 TBq/mmol	endogenous	V	50 µCi / 1.85 MBq	1.483,50

Name/Title:

Organization:

Phone No:

Address:

Fax No.:

City, Zip Code:

Radioisotope: specific Activity:

Chemical Name of Product:

Quantity needed:

Literature References:

Suggested Method of Synthesis:

Structure and Position of Label

Type of Service Desired

1. Custom synthesis
 - a. Carbon-14
 - b. Sulfur-35
 - c. Phosphorus-32
 - d. Tritium
 - i. Catalytic reduction with tritium gas
 - ii. Reduction with sodium borohydride
 - iii. Reduction with lithium aluminum hydride
 - iv. Tritium gas exposure
 - v. Tritiated water exchange
 - vi. N-methylation using methyl iodide-³H]
 - e. Iodination Service using [¹²⁵I]

Special Instructions.

Recommended Method(s) of Purification

1. TLC (silica gel) (cellulose)
Solvent System
2. Column Chromatography
Column Packing
Solvents
3. HPLC
Column and Conditions
4. Paper Chromatography
Solvent System

Additional Comments:

Is this product suitable for addition to BIOTREND's catalog?

(If the product appears to be of potential interest to other users, we may subsidize the cost of custom synthesis).

Note: For prompt quotations, please provide the above information by fax.

BIOTREND (+49 / (0) 221 9 49 83 25)

.....

.....

.....

Technical Service

Please feel free to call us at +49 221 9 49 83 20, for any questions, comments, complaints, requests or suggestions for new products. If you prefer to fax us your information, please call: +49 221 9 49 83 25 or e-mail: jaeger@biotrend.com

Our experts are available to help you with any technical questions you may have. Every attempt will be made to satisfy your needs or requests.

Tritium Labeling Service

BIOTREND routinely offers a variety of tritium labeling services. Our basic tritium labeling service includes removal of catalyst and labile tritium. Purification will be done at extra cost which will depend on the purification method required. The following listing details the most commonly used tritium labeling services:

- A. *Catalytic Reduction with Tritium Gas*
This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors.
- B. *Reduction with Sodium Borohydride [³H]*
This procedure is rather inexpensive and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, etc.
- C. *Reduction with Lithium Aluminum Hydride [³H]*
This procedure offers products at almost theoretical specific activities.
- D. *Tritium Gas Exposure Labeling Service*
This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst.
- E. *Tritiated Water Exchange Labeling Service*
In this procedure the precursor is heated in the presence of tritiated water.
- F. *N-Methylation using Methyl Iodide [³H]*
This procedure is usually employed to prepare N-methyl [³H] products by treating appropriate des-methyl precursors with high specific activity methyl iodide [³H].

We will be happy to discuss your individual requirements and provide price quotations for the above services. Please call or fax us the details of the product you require and we will respond with a detailed quotation as soon as possible.

Iodine-Labeling Service

BIOTREND Chemikalien GmbH will provide quotations on the iodination of biologically active substances using [¹²⁵I]. We will undertake the monoiodination of peptides at specific or defined positions.

The iodinated peptides are purified by state of the art HPLC techniques. Each product is accompanied by a detailed analytical data sheet and HPLC chromatogram.

Please call us at +49 221 9 49 83 20 or preferably fax us at +49 221 9 49 83 25 the appropriate information for prompt quotations.

Enquiry

BIOTREND Chemikalien GmbH
Im Technologiezentrum Köln
Eupener Str. 157 • D-50933 Cologne
Tel. +49 (0) 22 1/9 49 83 20
Fax. +49 (0) 22 1/9 49 83 25
jaeger@biotrend.com
www.biotrend.com

From:

Name: Date:

University/Company:

Institute/Department:

Street:

Area Code:Town:

Tel:.....FAX:E-Mail:

Products:

- Immunochemicals**
Primary Antibodies, Secondary Antibodies
- Cytokines
- Neurochemicals**
Ligands and Signal Transduction Reagents
- Radiolabeled Chemicals, [³H] [¹⁴C] [³⁵S][¹²⁵I]**
- Diabetes Research Reagents**
- cAMP, cGMP RIA, EIA
- Assay Designs (PerSeptive Biosystems)
- Chemiluminescence-Immunoassays (CLIA)
Prostaglandins
- Apoptosis Products
- Lipids and Sphingolipids**
Fluorescent Dyes/Indicators
Protein Stabilizer
- Immuno-PCR (IMPERACER Technology)**

Further Information on:

Please delete me from the mailing list.

Customized Services:

- Antibody Production**
(hosts are : Rabbit, Goat, Pig, Donkey, Chicken etc.)
- Conjugation of Peptides and Antibodies**
(FITC, Alk. Phos., HRP, Biotin, Gold)
- Peptide Syntheses**
(from mg's to g's)
- Customized Tritiation [³H₂]**
(Catalytic Reductions with Curie amounts)
- Customized Iodination [¹²⁵I]**
(Peptides, Growth Factors, Antibodies,
Organic Compounds)
- Radiochemical Syntheses [³H, ¹⁴C]**
- Purification of Radiochemicals [³H, ¹⁴C, ¹²⁵I]**
- Workshops**
Immuno-PCR (IMPERACER Technology)
- Production of your monoclonal Antibodies
- BIOTREND catalogues as Excel-files on CD-ROM**
- Luminex Technology



BIOTREND Chemikalien GmbH
Im Technologiezentrum Köln
Eupener Str. 157 • D-50933 Cologne
Tel. +49 (0) 221/9 49 83 20
Fax. +49 (0) 221/9 49 83 25
jaeger@biotrend.com
www.biotrend.com

